# PeptideScanner evidence objects: Carfilzomib

Every published version of the records placed with Carfilzomib, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json. Selected public evidence only; not medical advice.

- Objects: 62
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct01080391-carfilzomib-v1"></a>

## ClinicalTrials.gov record NCT01080391

> PeptideScanner retained ClinicalTrials.gov record NCT01080391 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-09-21, and PeptideScanner's reviewed identity mapping was carfilzomib.

- Evidence object: `story:clinicaltrials-gov-nct01080391-carfilzomib:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-09-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01080391-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01080391-carfilzomib-v1
- Content SHA-256: `73da0d70762a5429ecfa052e03d0280076e2091cdb4fe2138c93653b448ff3cf`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01080391 ([`ctg-observation-nct01080391-2022-09-21-89649f287120`](#source-ctg-observation-nct01080391-2022-09-21-89649f287120))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01080391 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-09-21, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct01080391-2022-09-21-89649f287120`](#source-ctg-observation-nct01080391-2022-09-21-89649f287120))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01080391 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-09-21, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct01080391-2022-09-21-89649f287120`](#source-ctg-observation-nct01080391-2022-09-21-89649f287120))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01080391-2022-09-21-89649f287120`](#source-ctg-observation-nct01080391-2022-09-21-89649f287120))

### Sources

<a id="source-ctg-observation-nct01080391-2022-09-21-89649f287120"></a>
- **ClinicalTrials.gov record NCT01080391 · retained source version 2022-09-21:89649f287120384d79c226754631149a94712f80f83b94d80abe1a82e14bf564** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01080391) (`ctg-observation-nct01080391-2022-09-21-89649f287120`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01080391." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01080391-carfilzomib-v1 SHA-256: 73da0d70762a5429ecfa052e03d0280076e2091cdb4fe2138c93653b448ff3cf.

---

<a id="clinicaltrials-gov-nct01302392-carfilzomib-v1"></a>

## ClinicalTrials.gov record NCT01302392

> PeptideScanner retained ClinicalTrials.gov record NCT01302392 at 2026-11-16T17:39:29.005Z. Its registry update date was 2017-05-02, and PeptideScanner's reviewed identity mapping was carfilzomib.

- Evidence object: `story:clinicaltrials-gov-nct01302392-carfilzomib:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-05-02
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01302392-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01302392-carfilzomib-v1
- Content SHA-256: `3ecfe945ffc7ed5bd8d9a9de93f522b0cf77fcc1e7ed3e66056473071177f458`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01302392 ([`ctg-observation-nct01302392-2017-05-02-0a16521d1c3f`](#source-ctg-observation-nct01302392-2017-05-02-0a16521d1c3f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01302392 at 2026-11-16T17:39:29.005Z. Its registry update date was 2017-05-02, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct01302392-2017-05-02-0a16521d1c3f`](#source-ctg-observation-nct01302392-2017-05-02-0a16521d1c3f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01302392 at 2026-11-16T17:39:29.005Z. Its registry update date was 2017-05-02, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct01302392-2017-05-02-0a16521d1c3f`](#source-ctg-observation-nct01302392-2017-05-02-0a16521d1c3f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01302392-2017-05-02-0a16521d1c3f`](#source-ctg-observation-nct01302392-2017-05-02-0a16521d1c3f))

### Sources

<a id="source-ctg-observation-nct01302392-2017-05-02-0a16521d1c3f"></a>
- **ClinicalTrials.gov record NCT01302392 · retained source version 2017-05-02:0a16521d1c3f9f663db7b98c7f51362c6175ea91d4e0035beb226af37acbd6ec** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01302392) (`ctg-observation-nct01302392-2017-05-02-0a16521d1c3f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01302392." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01302392-carfilzomib-v1 SHA-256: 3ecfe945ffc7ed5bd8d9a9de93f522b0cf77fcc1e7ed3e66056473071177f458.

---

<a id="clinicaltrials-gov-nct01559935-carfilzomib-v1"></a>

## ClinicalTrials.gov record NCT01559935

> PeptideScanner retained ClinicalTrials.gov record NCT01559935 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was carfilzomib.

- Evidence object: `story:clinicaltrials-gov-nct01559935-carfilzomib:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-29
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01559935-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01559935-carfilzomib-v1
- Content SHA-256: `53507780b55a8f47cb1fc70cfa23884f5accb31b5db480b21dcbfcecaba8d28c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01559935 ([`ctg-observation-nct01559935-2026-09-29-4536ef583a7f`](#source-ctg-observation-nct01559935-2026-09-29-4536ef583a7f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01559935 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct01559935-2026-09-29-4536ef583a7f`](#source-ctg-observation-nct01559935-2026-09-29-4536ef583a7f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01559935 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct01559935-2026-09-29-4536ef583a7f`](#source-ctg-observation-nct01559935-2026-09-29-4536ef583a7f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01559935-2026-09-29-4536ef583a7f`](#source-ctg-observation-nct01559935-2026-09-29-4536ef583a7f))

### Sources

<a id="source-ctg-observation-nct01559935-2026-09-29-4536ef583a7f"></a>
- **ClinicalTrials.gov record NCT01559935 · retained source version 2026-09-29:4536ef583a7f24062f8421663f6ff38c481ccf4e16740a8bec9c7fc2cbfbd651** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01559935) (`ctg-observation-nct01559935-2026-09-29-4536ef583a7f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01559935." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01559935-carfilzomib-v1 SHA-256: 53507780b55a8f47cb1fc70cfa23884f5accb31b5db480b21dcbfcecaba8d28c.

---

<a id="clinicaltrials-gov-nct01568866-carfilzomib-v1"></a>

## ClinicalTrials.gov record NCT01568866

> PeptideScanner retained ClinicalTrials.gov record NCT01568866 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-11-14, and PeptideScanner's reviewed identity mapping was carfilzomib.

- Evidence object: `story:clinicaltrials-gov-nct01568866-carfilzomib:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-11-14
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01568866-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01568866-carfilzomib-v1
- Content SHA-256: `c435d3438487cbfe7f10a8d362446dafd53ae0a03a340bd4f4af2f841bb5d97a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01568866 ([`ctg-observation-nct01568866-2022-11-14-6c7b7cc11ec6`](#source-ctg-observation-nct01568866-2022-11-14-6c7b7cc11ec6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01568866 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-11-14, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct01568866-2022-11-14-6c7b7cc11ec6`](#source-ctg-observation-nct01568866-2022-11-14-6c7b7cc11ec6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01568866 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-11-14, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct01568866-2022-11-14-6c7b7cc11ec6`](#source-ctg-observation-nct01568866-2022-11-14-6c7b7cc11ec6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01568866-2022-11-14-6c7b7cc11ec6`](#source-ctg-observation-nct01568866-2022-11-14-6c7b7cc11ec6))

### Sources

<a id="source-ctg-observation-nct01568866-2022-11-14-6c7b7cc11ec6"></a>
- **ClinicalTrials.gov record NCT01568866 · retained source version 2022-11-14:6c7b7cc11ec670b74756e7fdd2584949df5baf45f63b7f9436e091118cef1903** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01568866) (`ctg-observation-nct01568866-2022-11-14-6c7b7cc11ec6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01568866." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01568866-carfilzomib-v1 SHA-256: c435d3438487cbfe7f10a8d362446dafd53ae0a03a340bd4f4af2f841bb5d97a.

---

<a id="clinicaltrials-gov-nct01572480-carfilzomib-v1"></a>

## ClinicalTrials.gov record NCT01572480

> PeptideScanner retained ClinicalTrials.gov record NCT01572480 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-03-10, and PeptideScanner's reviewed identity mapping was carfilzomib.

- Evidence object: `story:clinicaltrials-gov-nct01572480-carfilzomib:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-10
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01572480-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01572480-carfilzomib-v1
- Content SHA-256: `0c5bdfba57bcdaa9901641dc1d43d74a8bcac3edf7292ad8a712107b22eb72ce`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01572480 ([`ctg-observation-nct01572480-2026-03-10-66be8e88049a`](#source-ctg-observation-nct01572480-2026-03-10-66be8e88049a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01572480 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-03-10, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct01572480-2026-03-10-66be8e88049a`](#source-ctg-observation-nct01572480-2026-03-10-66be8e88049a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01572480 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-03-10, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct01572480-2026-03-10-66be8e88049a`](#source-ctg-observation-nct01572480-2026-03-10-66be8e88049a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01572480-2026-03-10-66be8e88049a`](#source-ctg-observation-nct01572480-2026-03-10-66be8e88049a))

### Sources

<a id="source-ctg-observation-nct01572480-2026-03-10-66be8e88049a"></a>
- **ClinicalTrials.gov record NCT01572480 · retained source version 2026-03-10:66be8e88049aca697e05756b62076c3a6801364650ecb772b2077a64987e8325** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01572480) (`ctg-observation-nct01572480-2026-03-10-66be8e88049a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01572480." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01572480-carfilzomib-v1 SHA-256: 0c5bdfba57bcdaa9901641dc1d43d74a8bcac3edf7292ad8a712107b22eb72ce.

---

<a id="clinicaltrials-gov-nct01813227-carfilzomib-v1"></a>

## ClinicalTrials.gov record NCT01813227

> PeptideScanner retained ClinicalTrials.gov record NCT01813227 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-04-03, and PeptideScanner's reviewed identity mapping was carfilzomib.

- Evidence object: `story:clinicaltrials-gov-nct01813227-carfilzomib:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-03
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01813227-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01813227-carfilzomib-v1
- Content SHA-256: `d66abf2a3130d59ccf3f8f74fbfd75d8868a72cc0aeb24821c130ff5f967cfcb`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01813227 ([`ctg-observation-nct01813227-2026-04-03-fce89bfd9acc`](#source-ctg-observation-nct01813227-2026-04-03-fce89bfd9acc))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01813227 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-04-03, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct01813227-2026-04-03-fce89bfd9acc`](#source-ctg-observation-nct01813227-2026-04-03-fce89bfd9acc))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01813227 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-04-03, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct01813227-2026-04-03-fce89bfd9acc`](#source-ctg-observation-nct01813227-2026-04-03-fce89bfd9acc))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01813227-2026-04-03-fce89bfd9acc`](#source-ctg-observation-nct01813227-2026-04-03-fce89bfd9acc))

### Sources

<a id="source-ctg-observation-nct01813227-2026-04-03-fce89bfd9acc"></a>
- **ClinicalTrials.gov record NCT01813227 · retained source version 2026-04-03:fce89bfd9acc2523abb150658e3dee886628ce67944a42c94988ee2a5a2941f5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01813227) (`ctg-observation-nct01813227-2026-04-03-fce89bfd9acc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01813227." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01813227-carfilzomib-v1 SHA-256: d66abf2a3130d59ccf3f8f74fbfd75d8868a72cc0aeb24821c130ff5f967cfcb.

---

<a id="clinicaltrials-gov-nct01816971-carfilzomib-v1"></a>

## ClinicalTrials.gov record NCT01816971

> PeptideScanner retained ClinicalTrials.gov record NCT01816971 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was carfilzomib.

- Evidence object: `story:clinicaltrials-gov-nct01816971-carfilzomib:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01816971-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01816971-carfilzomib-v1
- Content SHA-256: `7b0d46cf38b7ccf1b6c3e4147cb6459849d9914d905f6c4c035d8bcbe70e9be6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01816971 ([`ctg-observation-nct01816971-2026-04-21-0a400f687b3c`](#source-ctg-observation-nct01816971-2026-04-21-0a400f687b3c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01816971 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct01816971-2026-04-21-0a400f687b3c`](#source-ctg-observation-nct01816971-2026-04-21-0a400f687b3c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01816971 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct01816971-2026-04-21-0a400f687b3c`](#source-ctg-observation-nct01816971-2026-04-21-0a400f687b3c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01816971-2026-04-21-0a400f687b3c`](#source-ctg-observation-nct01816971-2026-04-21-0a400f687b3c))

### Sources

<a id="source-ctg-observation-nct01816971-2026-04-21-0a400f687b3c"></a>
- **ClinicalTrials.gov record NCT01816971 · retained source version 2026-04-21:0a400f687b3c3976dc1f61dd5ff4d5bc026c4198a92f9af8174b1278158f17b2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01816971) (`ctg-observation-nct01816971-2026-04-21-0a400f687b3c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01816971." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01816971-carfilzomib-v1 SHA-256: 7b0d46cf38b7ccf1b6c3e4147cb6459849d9914d905f6c4c035d8bcbe70e9be6.

---

<a id="clinicaltrials-gov-nct01818752-carfilzomib-v1"></a>

## ClinicalTrials.gov record NCT01818752

> PeptideScanner retained ClinicalTrials.gov record NCT01818752 at 2026-11-16T17:39:29.005Z. Its registry update date was 2019-08-26, and PeptideScanner's reviewed identity mapping was carfilzomib.

- Evidence object: `story:clinicaltrials-gov-nct01818752-carfilzomib:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-08-26
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01818752-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01818752-carfilzomib-v1
- Content SHA-256: `9239a26660fc305b6691ed6e7c2a929e6495e7855dfe72c9b0aa082fa2d9df67`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01818752 ([`ctg-observation-nct01818752-2019-08-26-210b8b4dde90`](#source-ctg-observation-nct01818752-2019-08-26-210b8b4dde90))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01818752 at 2026-11-16T17:39:29.005Z. Its registry update date was 2019-08-26, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct01818752-2019-08-26-210b8b4dde90`](#source-ctg-observation-nct01818752-2019-08-26-210b8b4dde90))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01818752 at 2026-11-16T17:39:29.005Z. Its registry update date was 2019-08-26, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct01818752-2019-08-26-210b8b4dde90`](#source-ctg-observation-nct01818752-2019-08-26-210b8b4dde90))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01818752-2019-08-26-210b8b4dde90`](#source-ctg-observation-nct01818752-2019-08-26-210b8b4dde90))

### Sources

<a id="source-ctg-observation-nct01818752-2019-08-26-210b8b4dde90"></a>
- **ClinicalTrials.gov record NCT01818752 · retained source version 2019-08-26:210b8b4dde9012b539229d8df5e10100dd891fe344408235878c089dace5a624** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01818752) (`ctg-observation-nct01818752-2019-08-26-210b8b4dde90`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01818752." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct01818752-carfilzomib-v1 SHA-256: 9239a26660fc305b6691ed6e7c2a929e6495e7855dfe72c9b0aa082fa2d9df67.

---

<a id="clinicaltrials-gov-nct02412878-carfilzomib-v1"></a>

## ClinicalTrials.gov record NCT02412878

> PeptideScanner retained ClinicalTrials.gov record NCT02412878 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-09-23, and PeptideScanner's reviewed identity mapping was carfilzomib.

- Evidence object: `story:clinicaltrials-gov-nct02412878-carfilzomib:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-09-23
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02412878-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct02412878-carfilzomib-v1
- Content SHA-256: `c157754d2066966e4b07ee40d722bbea33640881250f6fe34c6fccaffacd304f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02412878 ([`ctg-observation-nct02412878-2022-09-23-10b153c11789`](#source-ctg-observation-nct02412878-2022-09-23-10b153c11789))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02412878 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-09-23, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct02412878-2022-09-23-10b153c11789`](#source-ctg-observation-nct02412878-2022-09-23-10b153c11789))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02412878 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-09-23, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct02412878-2022-09-23-10b153c11789`](#source-ctg-observation-nct02412878-2022-09-23-10b153c11789))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02412878-2022-09-23-10b153c11789`](#source-ctg-observation-nct02412878-2022-09-23-10b153c11789))

### Sources

<a id="source-ctg-observation-nct02412878-2022-09-23-10b153c11789"></a>
- **ClinicalTrials.gov record NCT02412878 · retained source version 2022-09-23:10b153c11789fce2251217cdfaa3c645b13e363497a4ff7989264f24ef60fcb4** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02412878) (`ctg-observation-nct02412878-2022-09-23-10b153c11789`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02412878." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct02412878-carfilzomib-v1 SHA-256: c157754d2066966e4b07ee40d722bbea33640881250f6fe34c6fccaffacd304f.

---

<a id="clinicaltrials-gov-nct02773030-carfilzomib-v1"></a>

## ClinicalTrials.gov record NCT02773030

> PeptideScanner retained ClinicalTrials.gov record NCT02773030 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-03-20, and PeptideScanner's reviewed identity mapping was carfilzomib.

- Evidence object: `story:clinicaltrials-gov-nct02773030-carfilzomib:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02773030-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct02773030-carfilzomib-v1
- Content SHA-256: `a1a43eeeaaf90192d7becfe18038bb54e1b3e694af32441c776658c29aee40d8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02773030 ([`ctg-observation-nct02773030-2026-03-20-35134d4f13f2`](#source-ctg-observation-nct02773030-2026-03-20-35134d4f13f2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02773030 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-03-20, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct02773030-2026-03-20-35134d4f13f2`](#source-ctg-observation-nct02773030-2026-03-20-35134d4f13f2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02773030 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-03-20, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct02773030-2026-03-20-35134d4f13f2`](#source-ctg-observation-nct02773030-2026-03-20-35134d4f13f2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02773030-2026-03-20-35134d4f13f2`](#source-ctg-observation-nct02773030-2026-03-20-35134d4f13f2))

### Sources

<a id="source-ctg-observation-nct02773030-2026-03-20-35134d4f13f2"></a>
- **ClinicalTrials.gov record NCT02773030 · retained source version 2026-03-20:35134d4f13f2f0c058fae3524cbdab95dea8c7a47fd247c73eec3ba35ed3a8c0** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02773030) (`ctg-observation-nct02773030-2026-03-20-35134d4f13f2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02773030." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct02773030-carfilzomib-v1 SHA-256: a1a43eeeaaf90192d7becfe18038bb54e1b3e694af32441c776658c29aee40d8.

---

<a id="clinicaltrials-gov-nct02937571-carfilzomib-v1"></a>

## ClinicalTrials.gov record NCT02937571

> PeptideScanner retained ClinicalTrials.gov record NCT02937571 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-11-20, and PeptideScanner's reviewed identity mapping was carfilzomib.

- Evidence object: `story:clinicaltrials-gov-nct02937571-carfilzomib:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-11-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02937571-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct02937571-carfilzomib-v1
- Content SHA-256: `70cfa150736138ee948b701de755fbaccdd8451f3ba195ebd099df84f1c876ba`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02937571 ([`ctg-observation-nct02937571-2025-11-20-dd3d3509385e`](#source-ctg-observation-nct02937571-2025-11-20-dd3d3509385e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02937571 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-11-20, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct02937571-2025-11-20-dd3d3509385e`](#source-ctg-observation-nct02937571-2025-11-20-dd3d3509385e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02937571 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-11-20, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct02937571-2025-11-20-dd3d3509385e`](#source-ctg-observation-nct02937571-2025-11-20-dd3d3509385e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02937571-2025-11-20-dd3d3509385e`](#source-ctg-observation-nct02937571-2025-11-20-dd3d3509385e))

### Sources

<a id="source-ctg-observation-nct02937571-2025-11-20-dd3d3509385e"></a>
- **ClinicalTrials.gov record NCT02937571 · retained source version 2025-11-20:dd3d3509385e62771cc4a7ce27b9f50520c246705a3a24be7ad2bf14aeb3fb22** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02937571) (`ctg-observation-nct02937571-2025-11-20-dd3d3509385e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02937571." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct02937571-carfilzomib-v1 SHA-256: 70cfa150736138ee948b701de755fbaccdd8451f3ba195ebd099df84f1c876ba.

---

<a id="clinicaltrials-gov-nct02969837-carfilzomib-v1"></a>

## ClinicalTrials.gov record NCT02969837

> PeptideScanner retained ClinicalTrials.gov record NCT02969837 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-01-16, and PeptideScanner's reviewed identity mapping was carfilzomib.

- Evidence object: `story:clinicaltrials-gov-nct02969837-carfilzomib:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-01-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02969837-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct02969837-carfilzomib-v1
- Content SHA-256: `d3732db5f19de6897f80ae6fc0e0328f3536261342903552282d4e1eb804d194`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02969837 ([`ctg-observation-nct02969837-2026-01-16-d6bc996c7e6d`](#source-ctg-observation-nct02969837-2026-01-16-d6bc996c7e6d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02969837 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-01-16, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct02969837-2026-01-16-d6bc996c7e6d`](#source-ctg-observation-nct02969837-2026-01-16-d6bc996c7e6d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02969837 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-01-16, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct02969837-2026-01-16-d6bc996c7e6d`](#source-ctg-observation-nct02969837-2026-01-16-d6bc996c7e6d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02969837-2026-01-16-d6bc996c7e6d`](#source-ctg-observation-nct02969837-2026-01-16-d6bc996c7e6d))

### Sources

<a id="source-ctg-observation-nct02969837-2026-01-16-d6bc996c7e6d"></a>
- **ClinicalTrials.gov record NCT02969837 · retained source version 2026-01-16:d6bc996c7e6d355a512d99bfe4d0392521061fbc9356063c64ede02784c8dc36** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02969837) (`ctg-observation-nct02969837-2026-01-16-d6bc996c7e6d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02969837." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct02969837-carfilzomib-v1 SHA-256: d3732db5f19de6897f80ae6fc0e0328f3536261342903552282d4e1eb804d194.

---

<a id="clinicaltrials-gov-nct03029234-carfilzomib-v1"></a>

## ClinicalTrials.gov record NCT03029234

> PeptideScanner retained ClinicalTrials.gov record NCT03029234 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-05-25, and PeptideScanner's reviewed identity mapping was carfilzomib.

- Evidence object: `story:clinicaltrials-gov-nct03029234-carfilzomib:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-05-25
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03029234-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03029234-carfilzomib-v1
- Content SHA-256: `6fed0f25a208f667484f48e8cacc311b217a5e07aecf3f41864a77412549fccd`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03029234 ([`ctg-observation-nct03029234-2022-05-25-500327e18925`](#source-ctg-observation-nct03029234-2022-05-25-500327e18925))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03029234 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-05-25, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct03029234-2022-05-25-500327e18925`](#source-ctg-observation-nct03029234-2022-05-25-500327e18925))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03029234 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-05-25, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct03029234-2022-05-25-500327e18925`](#source-ctg-observation-nct03029234-2022-05-25-500327e18925))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03029234-2022-05-25-500327e18925`](#source-ctg-observation-nct03029234-2022-05-25-500327e18925))

### Sources

<a id="source-ctg-observation-nct03029234-2022-05-25-500327e18925"></a>
- **ClinicalTrials.gov record NCT03029234 · retained source version 2022-05-25:500327e189250157491863dfce6b749084d50e4a4abcccadb88d9b1bb8f0a0d6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03029234) (`ctg-observation-nct03029234-2022-05-25-500327e18925`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03029234." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03029234-carfilzomib-v1 SHA-256: 6fed0f25a208f667484f48e8cacc311b217a5e07aecf3f41864a77412549fccd.

---

<a id="clinicaltrials-gov-nct03158688-carfilzomib-v1"></a>

## ClinicalTrials.gov record NCT03158688

> PeptideScanner retained ClinicalTrials.gov record NCT03158688 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-05-09, and PeptideScanner's reviewed identity mapping was carfilzomib.

- Evidence object: `story:clinicaltrials-gov-nct03158688-carfilzomib:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-05-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03158688-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03158688-carfilzomib-v1
- Content SHA-256: `6e779b0edbf58df888b2cbb8188e61ab2d0517cc0a17bf735e10ae2cb7e2e135`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03158688 ([`ctg-observation-nct03158688-2025-05-09-3024c8f61159`](#source-ctg-observation-nct03158688-2025-05-09-3024c8f61159))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03158688 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-05-09, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct03158688-2025-05-09-3024c8f61159`](#source-ctg-observation-nct03158688-2025-05-09-3024c8f61159))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03158688 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-05-09, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct03158688-2025-05-09-3024c8f61159`](#source-ctg-observation-nct03158688-2025-05-09-3024c8f61159))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03158688-2025-05-09-3024c8f61159`](#source-ctg-observation-nct03158688-2025-05-09-3024c8f61159))

### Sources

<a id="source-ctg-observation-nct03158688-2025-05-09-3024c8f61159"></a>
- **ClinicalTrials.gov record NCT03158688 · retained source version 2025-05-09:3024c8f61159fbce0902ef734942dbd31db3ca8a2264d8271427036faab0b960** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03158688) (`ctg-observation-nct03158688-2025-05-09-3024c8f61159`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03158688." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03158688-carfilzomib-v1 SHA-256: 6e779b0edbf58df888b2cbb8188e61ab2d0517cc0a17bf735e10ae2cb7e2e135.

---

<a id="clinicaltrials-gov-nct03275285-carfilzomib-v1"></a>

## ClinicalTrials.gov record NCT03275285

> PeptideScanner retained ClinicalTrials.gov record NCT03275285 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-02-09, and PeptideScanner's reviewed identity mapping was carfilzomib.

- Evidence object: `story:clinicaltrials-gov-nct03275285-carfilzomib:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-02-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03275285-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03275285-carfilzomib-v1
- Content SHA-256: `46765c1bcdd810e0bfb946973c034271438c4fb744342afff8b10025d3007234`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03275285 ([`ctg-observation-nct03275285-2026-02-09-c549d671b1b5`](#source-ctg-observation-nct03275285-2026-02-09-c549d671b1b5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03275285 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-02-09, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct03275285-2026-02-09-c549d671b1b5`](#source-ctg-observation-nct03275285-2026-02-09-c549d671b1b5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03275285 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-02-09, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct03275285-2026-02-09-c549d671b1b5`](#source-ctg-observation-nct03275285-2026-02-09-c549d671b1b5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03275285-2026-02-09-c549d671b1b5`](#source-ctg-observation-nct03275285-2026-02-09-c549d671b1b5))

### Sources

<a id="source-ctg-observation-nct03275285-2026-02-09-c549d671b1b5"></a>
- **ClinicalTrials.gov record NCT03275285 · retained source version 2026-02-09:c549d671b1b5c29c4951300686ad20f08b9156fe3c139ac4ddb2c98d2776c2d7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03275285) (`ctg-observation-nct03275285-2026-02-09-c549d671b1b5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03275285." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03275285-carfilzomib-v1 SHA-256: 46765c1bcdd810e0bfb946973c034271438c4fb744342afff8b10025d3007234.

---

<a id="clinicaltrials-gov-nct03290950-carfilzomib-v1"></a>

## ClinicalTrials.gov record NCT03290950

> PeptideScanner retained ClinicalTrials.gov record NCT03290950 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-05-29, and PeptideScanner's reviewed identity mapping was carfilzomib.

- Evidence object: `story:clinicaltrials-gov-nct03290950-carfilzomib:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-29
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03290950-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03290950-carfilzomib-v1
- Content SHA-256: `15d9b201fbb3f33feee203c9545fd81e2e0ca143abcfcc758f6fedc6021920b5`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03290950 ([`ctg-observation-nct03290950-2026-05-29-bfee11caa124`](#source-ctg-observation-nct03290950-2026-05-29-bfee11caa124))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03290950 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-05-29, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct03290950-2026-05-29-bfee11caa124`](#source-ctg-observation-nct03290950-2026-05-29-bfee11caa124))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03290950 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-05-29, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct03290950-2026-05-29-bfee11caa124`](#source-ctg-observation-nct03290950-2026-05-29-bfee11caa124))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03290950-2026-05-29-bfee11caa124`](#source-ctg-observation-nct03290950-2026-05-29-bfee11caa124))

### Sources

<a id="source-ctg-observation-nct03290950-2026-05-29-bfee11caa124"></a>
- **ClinicalTrials.gov record NCT03290950 · retained source version 2026-05-29:bfee11caa1240024e1e4fd95f4f2c1f691eb46232aec3f7c8331bd4bd497e57d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03290950) (`ctg-observation-nct03290950-2026-05-29-bfee11caa124`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03290950." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03290950-carfilzomib-v1 SHA-256: 15d9b201fbb3f33feee203c9545fd81e2e0ca143abcfcc758f6fedc6021920b5.

---

<a id="clinicaltrials-gov-nct03412565-carfilzomib-v1"></a>

## ClinicalTrials.gov record NCT03412565

> PeptideScanner retained ClinicalTrials.gov record NCT03412565 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-04-29, and PeptideScanner's reviewed identity mapping was carfilzomib.

- Evidence object: `story:clinicaltrials-gov-nct03412565-carfilzomib:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-04-29
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03412565-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03412565-carfilzomib-v1
- Content SHA-256: `402f7c79afcd85bd8517ca20d5674663e689fe034314c6ce2438e3db2dcdeb67`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03412565 ([`ctg-observation-nct03412565-2025-04-29-77b393a5c034`](#source-ctg-observation-nct03412565-2025-04-29-77b393a5c034))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03412565 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-04-29, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct03412565-2025-04-29-77b393a5c034`](#source-ctg-observation-nct03412565-2025-04-29-77b393a5c034))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03412565 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-04-29, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct03412565-2025-04-29-77b393a5c034`](#source-ctg-observation-nct03412565-2025-04-29-77b393a5c034))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03412565-2025-04-29-77b393a5c034`](#source-ctg-observation-nct03412565-2025-04-29-77b393a5c034))

### Sources

<a id="source-ctg-observation-nct03412565-2025-04-29-77b393a5c034"></a>
- **ClinicalTrials.gov record NCT03412565 · retained source version 2025-04-29:77b393a5c034c13199421c440826e85363ccb3804d082eeb6248d25c660ce633** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03412565) (`ctg-observation-nct03412565-2025-04-29-77b393a5c034`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03412565." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03412565-carfilzomib-v1 SHA-256: 402f7c79afcd85bd8517ca20d5674663e689fe034314c6ce2438e3db2dcdeb67.

---

<a id="clinicaltrials-gov-nct03416374-carfilzomib-v1"></a>

## ClinicalTrials.gov record NCT03416374

> PeptideScanner retained ClinicalTrials.gov record NCT03416374 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-09-27, and PeptideScanner's reviewed identity mapping was carfilzomib.

- Evidence object: `story:clinicaltrials-gov-nct03416374-carfilzomib:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-09-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03416374-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03416374-carfilzomib-v1
- Content SHA-256: `1b2ece425e53d16bf0bb444d4f796a981ff82365e85e667e9de04c560da1ebe2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03416374 ([`ctg-observation-nct03416374-2022-09-27-2491d74f5e75`](#source-ctg-observation-nct03416374-2022-09-27-2491d74f5e75))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03416374 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-09-27, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct03416374-2022-09-27-2491d74f5e75`](#source-ctg-observation-nct03416374-2022-09-27-2491d74f5e75))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03416374 at 2026-11-16T17:39:29.005Z. Its registry update date was 2022-09-27, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct03416374-2022-09-27-2491d74f5e75`](#source-ctg-observation-nct03416374-2022-09-27-2491d74f5e75))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03416374-2022-09-27-2491d74f5e75`](#source-ctg-observation-nct03416374-2022-09-27-2491d74f5e75))

### Sources

<a id="source-ctg-observation-nct03416374-2022-09-27-2491d74f5e75"></a>
- **ClinicalTrials.gov record NCT03416374 · retained source version 2022-09-27:2491d74f5e758df42659c73e3d42383c78cc148e5a3fb43e4782559edf134f12** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03416374) (`ctg-observation-nct03416374-2022-09-27-2491d74f5e75`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03416374." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03416374-carfilzomib-v1 SHA-256: 1b2ece425e53d16bf0bb444d4f796a981ff82365e85e667e9de04c560da1ebe2.

---

<a id="clinicaltrials-gov-nct03606577-carfilzomib-v1"></a>

## ClinicalTrials.gov record NCT03606577

> PeptideScanner retained ClinicalTrials.gov record NCT03606577 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was carfilzomib.

- Evidence object: `story:clinicaltrials-gov-nct03606577-carfilzomib:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-12
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03606577-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03606577-carfilzomib-v1
- Content SHA-256: `aa24d739a85f1564c8746d0d9a1795948f17ed520151a38dd612625dc9ddf3e3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03606577 ([`ctg-observation-nct03606577-2026-11-12-dfccdc11c35c`](#source-ctg-observation-nct03606577-2026-11-12-dfccdc11c35c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03606577 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct03606577-2026-11-12-dfccdc11c35c`](#source-ctg-observation-nct03606577-2026-11-12-dfccdc11c35c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03606577 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct03606577-2026-11-12-dfccdc11c35c`](#source-ctg-observation-nct03606577-2026-11-12-dfccdc11c35c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03606577-2026-11-12-dfccdc11c35c`](#source-ctg-observation-nct03606577-2026-11-12-dfccdc11c35c))

### Sources

<a id="source-ctg-observation-nct03606577-2026-11-12-dfccdc11c35c"></a>
- **ClinicalTrials.gov record NCT03606577 · retained source version 2026-11-12:dfccdc11c35cf0222f1eb4cbae36ff75c546dd07d7f0cf9cd1053b6f0ee4e29c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03606577) (`ctg-observation-nct03606577-2026-11-12-dfccdc11c35c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03606577." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03606577-carfilzomib-v1 SHA-256: aa24d739a85f1564c8746d0d9a1795948f17ed520151a38dd612625dc9ddf3e3.

---

<a id="clinicaltrials-gov-nct03859427-carfilzomib-v1"></a>

## ClinicalTrials.gov record NCT03859427

> PeptideScanner retained ClinicalTrials.gov record NCT03859427 at 2026-11-16T17:39:29.005Z. Its registry update date was 2024-08-13, and PeptideScanner's reviewed identity mapping was carfilzomib.

- Evidence object: `story:clinicaltrials-gov-nct03859427-carfilzomib:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-08-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03859427-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03859427-carfilzomib-v1
- Content SHA-256: `4902cb7d34600831cc7b8dc12026e95a1ccb347b44b02779388326d0a8d878c3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03859427 ([`ctg-observation-nct03859427-2024-08-13-ccba6d3325c0`](#source-ctg-observation-nct03859427-2024-08-13-ccba6d3325c0))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03859427 at 2026-11-16T17:39:29.005Z. Its registry update date was 2024-08-13, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct03859427-2024-08-13-ccba6d3325c0`](#source-ctg-observation-nct03859427-2024-08-13-ccba6d3325c0))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03859427 at 2026-11-16T17:39:29.005Z. Its registry update date was 2024-08-13, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct03859427-2024-08-13-ccba6d3325c0`](#source-ctg-observation-nct03859427-2024-08-13-ccba6d3325c0))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03859427-2024-08-13-ccba6d3325c0`](#source-ctg-observation-nct03859427-2024-08-13-ccba6d3325c0))

### Sources

<a id="source-ctg-observation-nct03859427-2024-08-13-ccba6d3325c0"></a>
- **ClinicalTrials.gov record NCT03859427 · retained source version 2024-08-13:ccba6d3325c0121f74f96c54ed9166734dc36ecce510c3a7020e2f11e1a90a6f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03859427) (`ctg-observation-nct03859427-2024-08-13-ccba6d3325c0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03859427." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03859427-carfilzomib-v1 SHA-256: 4902cb7d34600831cc7b8dc12026e95a1ccb347b44b02779388326d0a8d878c3.

---

<a id="clinicaltrials-gov-nct03934684-carfilzomib-v1"></a>

## ClinicalTrials.gov record NCT03934684

> PeptideScanner retained ClinicalTrials.gov record NCT03934684 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-05-11, and PeptideScanner's reviewed identity mapping was carfilzomib.

- Evidence object: `story:clinicaltrials-gov-nct03934684-carfilzomib:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-11
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03934684-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03934684-carfilzomib-v1
- Content SHA-256: `b51e42587f0928b7053ac24e533cba1a97a7cb4ee5dd15ed3b941835f3b15e54`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03934684 ([`ctg-observation-nct03934684-2026-05-11-f5b99bda2f5d`](#source-ctg-observation-nct03934684-2026-05-11-f5b99bda2f5d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03934684 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-05-11, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct03934684-2026-05-11-f5b99bda2f5d`](#source-ctg-observation-nct03934684-2026-05-11-f5b99bda2f5d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03934684 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-05-11, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct03934684-2026-05-11-f5b99bda2f5d`](#source-ctg-observation-nct03934684-2026-05-11-f5b99bda2f5d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03934684-2026-05-11-f5b99bda2f5d`](#source-ctg-observation-nct03934684-2026-05-11-f5b99bda2f5d))

### Sources

<a id="source-ctg-observation-nct03934684-2026-05-11-f5b99bda2f5d"></a>
- **ClinicalTrials.gov record NCT03934684 · retained source version 2026-05-11:f5b99bda2f5d85d4c3721bdd416fa3e6fa684fbb2e64210d033508833f59d558** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03934684) (`ctg-observation-nct03934684-2026-05-11-f5b99bda2f5d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03934684." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct03934684-carfilzomib-v1 SHA-256: b51e42587f0928b7053ac24e533cba1a97a7cb4ee5dd15ed3b941835f3b15e54.

---

<a id="clinicaltrials-gov-nct04191616-carfilzomib-v1"></a>

## ClinicalTrials.gov record NCT04191616

> PeptideScanner retained ClinicalTrials.gov record NCT04191616 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-09-04, and PeptideScanner's reviewed identity mapping was carfilzomib.

- Evidence object: `story:clinicaltrials-gov-nct04191616-carfilzomib:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-09-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04191616-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct04191616-carfilzomib-v1
- Content SHA-256: `b6641954d77cbc53836759cc57918d78211d7faef254a15743bc758d0966338c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04191616 ([`ctg-observation-nct04191616-2025-09-04-95ba873f4d20`](#source-ctg-observation-nct04191616-2025-09-04-95ba873f4d20))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04191616 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-09-04, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct04191616-2025-09-04-95ba873f4d20`](#source-ctg-observation-nct04191616-2025-09-04-95ba873f4d20))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04191616 at 2026-11-16T17:39:29.005Z. Its registry update date was 2025-09-04, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct04191616-2025-09-04-95ba873f4d20`](#source-ctg-observation-nct04191616-2025-09-04-95ba873f4d20))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04191616-2025-09-04-95ba873f4d20`](#source-ctg-observation-nct04191616-2025-09-04-95ba873f4d20))

### Sources

<a id="source-ctg-observation-nct04191616-2025-09-04-95ba873f4d20"></a>
- **ClinicalTrials.gov record NCT04191616 · retained source version 2025-09-04:95ba873f4d209e51cbd1e618189e1e9d1bc28300d65151e18cec3035fe8eb7cf** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04191616) (`ctg-observation-nct04191616-2025-09-04-95ba873f4d20`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04191616." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct04191616-carfilzomib-v1 SHA-256: b6641954d77cbc53836759cc57918d78211d7faef254a15743bc758d0966338c.

---

<a id="clinicaltrials-gov-nct04430894-carfilzomib-v1"></a>

## ClinicalTrials.gov record NCT04430894

> PeptideScanner retained ClinicalTrials.gov record NCT04430894 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-10-06, and PeptideScanner's reviewed identity mapping was carfilzomib.

- Evidence object: `story:clinicaltrials-gov-nct04430894-carfilzomib:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-06
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04430894-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct04430894-carfilzomib-v1
- Content SHA-256: `3870724c739142723535356ecc4661b6c6155d3479db9577bd47d81f151a7e28`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04430894 ([`ctg-observation-nct04430894-2026-10-06-bcf48c40d417`](#source-ctg-observation-nct04430894-2026-10-06-bcf48c40d417))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04430894 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-10-06, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct04430894-2026-10-06-bcf48c40d417`](#source-ctg-observation-nct04430894-2026-10-06-bcf48c40d417))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04430894 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-10-06, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct04430894-2026-10-06-bcf48c40d417`](#source-ctg-observation-nct04430894-2026-10-06-bcf48c40d417))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04430894-2026-10-06-bcf48c40d417`](#source-ctg-observation-nct04430894-2026-10-06-bcf48c40d417))

### Sources

<a id="source-ctg-observation-nct04430894-2026-10-06-bcf48c40d417"></a>
- **ClinicalTrials.gov record NCT04430894 · retained source version 2026-10-06:bcf48c40d4173ea316425b59de47917c2248375024fc22e8d06c042ea1d8b1ca** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04430894) (`ctg-observation-nct04430894-2026-10-06-bcf48c40d417`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04430894." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct04430894-carfilzomib-v1 SHA-256: 3870724c739142723535356ecc4661b6c6155d3479db9577bd47d81f151a7e28.

---

<a id="clinicaltrials-gov-nct04756401-carfilzomib-v1"></a>

## ClinicalTrials.gov record NCT04756401

> PeptideScanner retained ClinicalTrials.gov record NCT04756401 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-09-15, and PeptideScanner's reviewed identity mapping was carfilzomib.

- Evidence object: `story:clinicaltrials-gov-nct04756401-carfilzomib:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04756401-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct04756401-carfilzomib-v1
- Content SHA-256: `08c26e2411876def405c9b65e04aac5068e6489fa4cf1a1fc293d4f71e9e8213`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04756401 ([`ctg-observation-nct04756401-2026-09-15-cf07c59bd732`](#source-ctg-observation-nct04756401-2026-09-15-cf07c59bd732))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04756401 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-09-15, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct04756401-2026-09-15-cf07c59bd732`](#source-ctg-observation-nct04756401-2026-09-15-cf07c59bd732))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04756401 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-09-15, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct04756401-2026-09-15-cf07c59bd732`](#source-ctg-observation-nct04756401-2026-09-15-cf07c59bd732))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04756401-2026-09-15-cf07c59bd732`](#source-ctg-observation-nct04756401-2026-09-15-cf07c59bd732))

### Sources

<a id="source-ctg-observation-nct04756401-2026-09-15-cf07c59bd732"></a>
- **ClinicalTrials.gov record NCT04756401 · retained source version 2026-09-15:cf07c59bd732cece4059a26d15afabb6366c258706e3179823c69775298a6f17** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04756401) (`ctg-observation-nct04756401-2026-09-15-cf07c59bd732`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04756401." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct04756401-carfilzomib-v1 SHA-256: 08c26e2411876def405c9b65e04aac5068e6489fa4cf1a1fc293d4f71e9e8213.

---

<a id="clinicaltrials-gov-nct04925193-carfilzomib-v1"></a>

## ClinicalTrials.gov record NCT04925193

> PeptideScanner retained ClinicalTrials.gov record NCT04925193 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-10-02, and PeptideScanner's reviewed identity mapping was carfilzomib.

- Evidence object: `story:clinicaltrials-gov-nct04925193-carfilzomib:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-02
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04925193-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct04925193-carfilzomib-v1
- Content SHA-256: `d0a38baeda8e0f1ec093e7055a06c8b88c97ae394309b9cda0a62d1121e7bcdd`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04925193 ([`ctg-observation-nct04925193-2026-10-02-6b647fadad9e`](#source-ctg-observation-nct04925193-2026-10-02-6b647fadad9e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04925193 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-10-02, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct04925193-2026-10-02-6b647fadad9e`](#source-ctg-observation-nct04925193-2026-10-02-6b647fadad9e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04925193 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-10-02, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct04925193-2026-10-02-6b647fadad9e`](#source-ctg-observation-nct04925193-2026-10-02-6b647fadad9e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04925193-2026-10-02-6b647fadad9e`](#source-ctg-observation-nct04925193-2026-10-02-6b647fadad9e))

### Sources

<a id="source-ctg-observation-nct04925193-2026-10-02-6b647fadad9e"></a>
- **ClinicalTrials.gov record NCT04925193 · retained source version 2026-10-02:6b647fadad9e11b4fda50ef893df239297cd634cfa5d92121bd40250e91b33ad** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04925193) (`ctg-observation-nct04925193-2026-10-02-6b647fadad9e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04925193." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct04925193-carfilzomib-v1 SHA-256: d0a38baeda8e0f1ec093e7055a06c8b88c97ae394309b9cda0a62d1121e7bcdd.

---

<a id="clinicaltrials-gov-nct05497804-carfilzomib-v1"></a>

## ClinicalTrials.gov record NCT05497804

> PeptideScanner retained ClinicalTrials.gov record NCT05497804 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was carfilzomib.

- Evidence object: `story:clinicaltrials-gov-nct05497804-carfilzomib:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-02
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05497804-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct05497804-carfilzomib-v1
- Content SHA-256: `34dd1b3f1317688ae3a4929074692000ddb4914958480872f16f730a6db10b40`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05497804 ([`ctg-observation-nct05497804-2026-11-02-3775b4bee786`](#source-ctg-observation-nct05497804-2026-11-02-3775b4bee786))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05497804 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct05497804-2026-11-02-3775b4bee786`](#source-ctg-observation-nct05497804-2026-11-02-3775b4bee786))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05497804 at 2026-11-16T17:39:29.005Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct05497804-2026-11-02-3775b4bee786`](#source-ctg-observation-nct05497804-2026-11-02-3775b4bee786))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05497804-2026-11-02-3775b4bee786`](#source-ctg-observation-nct05497804-2026-11-02-3775b4bee786))

### Sources

<a id="source-ctg-observation-nct05497804-2026-11-02-3775b4bee786"></a>
- **ClinicalTrials.gov record NCT05497804 · retained source version 2026-11-02:3775b4bee7860b8cfc196c1b009c057e9af43e78066e8ba9694ce6ae752edb82** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05497804) (`ctg-observation-nct05497804-2026-11-02-3775b4bee786`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05497804." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct05497804-carfilzomib-v1 SHA-256: 34dd1b3f1317688ae3a4929074692000ddb4914958480872f16f730a6db10b40.

---

<a id="clinicaltrials-gov-nct06152575-carfilzomib-v1"></a>

## ClinicalTrials.gov record NCT06152575

> PeptideScanner retained ClinicalTrials.gov record NCT06152575 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was carfilzomib.

- Evidence object: `story:clinicaltrials-gov-nct06152575-carfilzomib:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-12
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06152575-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct06152575-carfilzomib-v1
- Content SHA-256: `aac7b8198d7c9c567066cb5f353a226fbe8432e66ac1f73c6c5f8b59d24c99aa`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06152575 ([`ctg-observation-nct06152575-2026-11-12-b40f3be6bfe9`](#source-ctg-observation-nct06152575-2026-11-12-b40f3be6bfe9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06152575 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct06152575-2026-11-12-b40f3be6bfe9`](#source-ctg-observation-nct06152575-2026-11-12-b40f3be6bfe9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06152575 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct06152575-2026-11-12-b40f3be6bfe9`](#source-ctg-observation-nct06152575-2026-11-12-b40f3be6bfe9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06152575-2026-11-12-b40f3be6bfe9`](#source-ctg-observation-nct06152575-2026-11-12-b40f3be6bfe9))

### Sources

<a id="source-ctg-observation-nct06152575-2026-11-12-b40f3be6bfe9"></a>
- **ClinicalTrials.gov record NCT06152575 · retained source version 2026-11-12:b40f3be6bfe9bf8a5151b90016cc17b95f069b01bcff5119e0510e701ab5382e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06152575) (`ctg-observation-nct06152575-2026-11-12-b40f3be6bfe9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06152575." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct06152575-carfilzomib-v1 SHA-256: aac7b8198d7c9c567066cb5f353a226fbe8432e66ac1f73c6c5f8b59d24c99aa.

---

<a id="clinicaltrials-gov-nct07555938-carfilzomib-v1"></a>

## ClinicalTrials.gov record NCT07555938

> PeptideScanner retained ClinicalTrials.gov record NCT07555938 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was carfilzomib.

- Evidence object: `story:clinicaltrials-gov-nct07555938-carfilzomib:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-10
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07555938-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct07555938-carfilzomib-v1
- Content SHA-256: `d1b74ce676f2afc895e6ce0965b8b8a01475613e536724995614379666d00c80`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07555938 ([`ctg-observation-nct07555938-2026-11-10-a49c9796a930`](#source-ctg-observation-nct07555938-2026-11-10-a49c9796a930))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07555938 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct07555938-2026-11-10-a49c9796a930`](#source-ctg-observation-nct07555938-2026-11-10-a49c9796a930))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07555938 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct07555938-2026-11-10-a49c9796a930`](#source-ctg-observation-nct07555938-2026-11-10-a49c9796a930))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07555938-2026-11-10-a49c9796a930`](#source-ctg-observation-nct07555938-2026-11-10-a49c9796a930))

### Sources

<a id="source-ctg-observation-nct07555938-2026-11-10-a49c9796a930"></a>
- **ClinicalTrials.gov record NCT07555938 · retained source version 2026-11-10:a49c9796a93023e4be137c8f04eba3fdeb0a373f7b1371acc7eb4b24b3b421de** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07555938) (`ctg-observation-nct07555938-2026-11-10-a49c9796a930`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07555938." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct07555938-carfilzomib-v1 SHA-256: d1b74ce676f2afc895e6ce0965b8b8a01475613e536724995614379666d00c80.

---

<a id="clinicaltrials-gov-nct07715903-carfilzomib-v1"></a>

## ClinicalTrials.gov record NCT07715903

> PeptideScanner retained ClinicalTrials.gov record NCT07715903 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was carfilzomib.

- Evidence object: `story:clinicaltrials-gov-nct07715903-carfilzomib:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-16
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07715903-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct07715903-carfilzomib-v1
- Content SHA-256: `a4cc2f5646092ae516a0a774bc5099e256b0f6d101aac832d9e504c2dcf977a6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07715903 ([`ctg-observation-nct07715903-2026-11-16-26eebf96af2f`](#source-ctg-observation-nct07715903-2026-11-16-26eebf96af2f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07715903 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct07715903-2026-11-16-26eebf96af2f`](#source-ctg-observation-nct07715903-2026-11-16-26eebf96af2f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07715903 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was carfilzomib. ([`ctg-observation-nct07715903-2026-11-16-26eebf96af2f`](#source-ctg-observation-nct07715903-2026-11-16-26eebf96af2f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07715903-2026-11-16-26eebf96af2f`](#source-ctg-observation-nct07715903-2026-11-16-26eebf96af2f))

### Sources

<a id="source-ctg-observation-nct07715903-2026-11-16-26eebf96af2f"></a>
- **ClinicalTrials.gov record NCT07715903 · retained source version 2026-11-16:26eebf96af2f6c9a1b392487c8c78d7a7fb6645919439c2f5c7b0aadf1c11585** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07715903) (`ctg-observation-nct07715903-2026-11-16-26eebf96af2f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07715903." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#clinicaltrials-gov-nct07715903-carfilzomib-v1 SHA-256: a4cc2f5646092ae516a0a774bc5099e256b0f6d101aac832d9e504c2dcf977a6.

---

<a id="fda-drugs-anda209330-v1"></a>

## Drugs@FDA application ANDA209330

> The official Drugs@FDA dataset lists original submission 1 for ANDA 209330 with status AP dated 2021-06-11, and names carfilzomib among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda209330:v1`
- Evidence domain: Regulatory
- Date in source: 2021-06-11
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda209330/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#fda-drugs-anda209330-v1
- Content SHA-256: `6cef73b07697a9d0b14add378306364ecc5b19bf06461d8622857e6f0598225c`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA209330 ([`fda-drugs-anda209330-2021-06-11-5dda10f64e7a`](#source-fda-drugs-anda209330-2021-06-11-5dda10f64e7a))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 209330 with status AP dated 2021-06-11, and names carfilzomib among the application record's active ingredients. ([`fda-drugs-anda209330-2021-06-11-5dda10f64e7a`](#source-fda-drugs-anda209330-2021-06-11-5dda10f64e7a))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 209330 with status AP dated 2021-06-11, and names carfilzomib among the application record's active ingredients. ([`fda-drugs-anda209330-2021-06-11-5dda10f64e7a`](#source-fda-drugs-anda209330-2021-06-11-5dda10f64e7a))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda209330-2021-06-11-5dda10f64e7a`](#source-fda-drugs-anda209330-2021-06-11-5dda10f64e7a))

### Sources

<a id="source-fda-drugs-anda209330-2021-06-11-5dda10f64e7a"></a>
- **Drugs@FDA application ANDA209330 · original submission status AP · 2021-06-11 · dataset 2026-11-16** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA209330%22&limit=1) (`fda-drugs-anda209330-2021-06-11-5dda10f64e7a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA209330." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#fda-drugs-anda209330-v1 SHA-256: 6cef73b07697a9d0b14add378306364ecc5b19bf06461d8622857e6f0598225c.

---

<a id="fda-drugs-anda209422-v1"></a>

## Drugs@FDA application ANDA209422

> The official Drugs@FDA dataset lists original submission 1 for ANDA 209422 with status AP dated 2019-09-09, and names carfilzomib among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda209422:v1`
- Evidence domain: Regulatory
- Date in source: 2019-09-09
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda209422/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#fda-drugs-anda209422-v1
- Content SHA-256: `0994d738e2a8810c270f13d8e3d9d976803827f834bd68051c6d2e3068d7be64`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA209422 ([`fda-drugs-anda209422-2019-09-09-bc87b6f86e64`](#source-fda-drugs-anda209422-2019-09-09-bc87b6f86e64))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 209422 with status AP dated 2019-09-09, and names carfilzomib among the application record's active ingredients. ([`fda-drugs-anda209422-2019-09-09-bc87b6f86e64`](#source-fda-drugs-anda209422-2019-09-09-bc87b6f86e64))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 209422 with status AP dated 2019-09-09, and names carfilzomib among the application record's active ingredients. ([`fda-drugs-anda209422-2019-09-09-bc87b6f86e64`](#source-fda-drugs-anda209422-2019-09-09-bc87b6f86e64))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda209422-2019-09-09-bc87b6f86e64`](#source-fda-drugs-anda209422-2019-09-09-bc87b6f86e64))

### Sources

<a id="source-fda-drugs-anda209422-2019-09-09-bc87b6f86e64"></a>
- **Drugs@FDA application ANDA209422 · original submission status AP · 2019-09-09 · dataset 2026-11-16** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA209422%22&limit=1) (`fda-drugs-anda209422-2019-09-09-bc87b6f86e64`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA209422." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#fda-drugs-anda209422-v1 SHA-256: 0994d738e2a8810c270f13d8e3d9d976803827f834bd68051c6d2e3068d7be64.

---

<a id="fda-drugs-anda209425-v1"></a>

## Drugs@FDA application ANDA209425

> The official Drugs@FDA dataset lists original submission 1 for ANDA 209425 with status AP dated 2020-03-16, and names carfilzomib among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda209425:v1`
- Evidence domain: Regulatory
- Date in source: 2020-03-16
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda209425/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#fda-drugs-anda209425-v1
- Content SHA-256: `9db3da6aaa65cbdcdd79268bbe0e82bd232fb5285507ae1518adb23b23de64b1`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA209425 ([`fda-drugs-anda209425-2020-03-16-83cf03306b3f`](#source-fda-drugs-anda209425-2020-03-16-83cf03306b3f))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 209425 with status AP dated 2020-03-16, and names carfilzomib among the application record's active ingredients. ([`fda-drugs-anda209425-2020-03-16-83cf03306b3f`](#source-fda-drugs-anda209425-2020-03-16-83cf03306b3f))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 209425 with status AP dated 2020-03-16, and names carfilzomib among the application record's active ingredients. ([`fda-drugs-anda209425-2020-03-16-83cf03306b3f`](#source-fda-drugs-anda209425-2020-03-16-83cf03306b3f))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda209425-2020-03-16-83cf03306b3f`](#source-fda-drugs-anda209425-2020-03-16-83cf03306b3f))

### Sources

<a id="source-fda-drugs-anda209425-2020-03-16-83cf03306b3f"></a>
- **Drugs@FDA application ANDA209425 · original submission status AP · 2020-03-16 · dataset 2026-11-16** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA209425%22&limit=1) (`fda-drugs-anda209425-2020-03-16-83cf03306b3f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA209425." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#fda-drugs-anda209425-v1 SHA-256: 9db3da6aaa65cbdcdd79268bbe0e82bd232fb5285507ae1518adb23b23de64b1.

---

<a id="fda-drugs-anda209526-v1"></a>

## Drugs@FDA application ANDA209526

> The official Drugs@FDA dataset lists original submission 1 for ANDA 209526 with status AP dated 2026-07-20, and names carfilzomib among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda209526:v1`
- Evidence domain: Regulatory
- Date in source: 2026-07-20
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda209526/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#fda-drugs-anda209526-v1
- Content SHA-256: `ce792e6ab3656d88d6857bfd5c4d315d20f6760b6045e1fc1f84b2a0e5dac1df`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA209526 ([`fda-drugs-anda209526-2026-07-20-331a03ad072e`](#source-fda-drugs-anda209526-2026-07-20-331a03ad072e))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 209526 with status AP dated 2026-07-20, and names carfilzomib among the application record's active ingredients. ([`fda-drugs-anda209526-2026-07-20-331a03ad072e`](#source-fda-drugs-anda209526-2026-07-20-331a03ad072e))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 209526 with status AP dated 2026-07-20, and names carfilzomib among the application record's active ingredients. ([`fda-drugs-anda209526-2026-07-20-331a03ad072e`](#source-fda-drugs-anda209526-2026-07-20-331a03ad072e))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda209526-2026-07-20-331a03ad072e`](#source-fda-drugs-anda209526-2026-07-20-331a03ad072e))

### Sources

<a id="source-fda-drugs-anda209526-2026-07-20-331a03ad072e"></a>
- **Drugs@FDA application ANDA209526 · original submission status AP · 2026-07-20 · dataset 2026-11-16** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA209526%22&limit=1) (`fda-drugs-anda209526-2026-07-20-331a03ad072e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA209526." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#fda-drugs-anda209526-v1 SHA-256: ce792e6ab3656d88d6857bfd5c4d315d20f6760b6045e1fc1f84b2a0e5dac1df.

---

<a id="fda-drugs-anda211185-v1"></a>

## Drugs@FDA application ANDA211185

> The official Drugs@FDA dataset lists original submission 1 for ANDA 211185 with status AP dated 2020-03-20, and names carfilzomib among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda211185:v1`
- Evidence domain: Regulatory
- Date in source: 2020-03-20
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda211185/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#fda-drugs-anda211185-v1
- Content SHA-256: `496b32b3ca323bea52622fba29df8ca89cd815cd559710b82c9c87cda100c924`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA211185 ([`fda-drugs-anda211185-2020-03-20-aa34c1f503ae`](#source-fda-drugs-anda211185-2020-03-20-aa34c1f503ae))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 211185 with status AP dated 2020-03-20, and names carfilzomib among the application record's active ingredients. ([`fda-drugs-anda211185-2020-03-20-aa34c1f503ae`](#source-fda-drugs-anda211185-2020-03-20-aa34c1f503ae))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 211185 with status AP dated 2020-03-20, and names carfilzomib among the application record's active ingredients. ([`fda-drugs-anda211185-2020-03-20-aa34c1f503ae`](#source-fda-drugs-anda211185-2020-03-20-aa34c1f503ae))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda211185-2020-03-20-aa34c1f503ae`](#source-fda-drugs-anda211185-2020-03-20-aa34c1f503ae))

### Sources

<a id="source-fda-drugs-anda211185-2020-03-20-aa34c1f503ae"></a>
- **Drugs@FDA application ANDA211185 · original submission status AP · 2020-03-20 · dataset 2026-11-16** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA211185%22&limit=1) (`fda-drugs-anda211185-2020-03-20-aa34c1f503ae`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA211185." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#fda-drugs-anda211185-v1 SHA-256: 496b32b3ca323bea52622fba29df8ca89cd815cd559710b82c9c87cda100c924.

---

<a id="fda-drugs-nda202714-v1"></a>

## Drugs@FDA application NDA202714

> The official Drugs@FDA dataset lists original submission 1 for NDA 202714 with status AP dated 2012-07-20, and names carfilzomib among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda202714:v1`
- Evidence domain: Regulatory
- Date in source: 2012-07-20
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda202714/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#fda-drugs-nda202714-v1
- Content SHA-256: `de8df92a18e36c501f7e2f28b124c280186c719226f65921fe667fef74d33002`

### Claims and source pins

#### Headline

Drugs@FDA application NDA202714 ([`fda-drugs-nda202714-2012-07-20-883b927fa7bb`](#source-fda-drugs-nda202714-2012-07-20-883b927fa7bb))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 202714 with status AP dated 2012-07-20, and names carfilzomib among the application record's active ingredients. ([`fda-drugs-nda202714-2012-07-20-883b927fa7bb`](#source-fda-drugs-nda202714-2012-07-20-883b927fa7bb))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 202714 with status AP dated 2012-07-20, and names carfilzomib among the application record's active ingredients. ([`fda-drugs-nda202714-2012-07-20-883b927fa7bb`](#source-fda-drugs-nda202714-2012-07-20-883b927fa7bb))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda202714-2012-07-20-883b927fa7bb`](#source-fda-drugs-nda202714-2012-07-20-883b927fa7bb))

### Sources

<a id="source-fda-drugs-nda202714-2012-07-20-883b927fa7bb"></a>
- **Drugs@FDA application NDA202714 · original submission status AP · 2012-07-20 · dataset 2026-11-16** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA202714%22&limit=1) (`fda-drugs-nda202714-2012-07-20-883b927fa7bb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA202714." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#fda-drugs-nda202714-v1 SHA-256: de8df92a18e36c501f7e2f28b124c280186c719226f65921fe667fef74d33002.

---

<a id="federal-register-2012-10154-v1"></a>

## Federal Register notice 2012-10154

> The Federal Register published notice 2012-10154, attributed to FDA and its parent HHS department, on 2012-04-27. Its official title is “Oncologic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Carfilzomib.

- Evidence object: `story:federal-register-2012-10154:v1`
- Evidence domain: Regulatory
- Date in source: 2012-04-27
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/federal-register-2012-10154/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#federal-register-2012-10154-v1
- Content SHA-256: `2418e27b7730cad00dc493f4ace3bafaca21d97df7c30e93a92a7d632d645571`

### Claims and source pins

#### Headline

Federal Register notice 2012-10154 ([`federal-register-2012-10154-49dd1da902a8`](#source-federal-register-2012-10154-49dd1da902a8))

#### Summary

The Federal Register published notice 2012-10154, attributed to FDA and its parent HHS department, on 2012-04-27. Its official title is “Oncologic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Carfilzomib. ([`federal-register-2012-10154-49dd1da902a8`](#source-federal-register-2012-10154-49dd1da902a8))

#### Paragraph 1

The Federal Register published notice 2012-10154, attributed to FDA and its parent HHS department, on 2012-04-27. Its official title is “Oncologic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Carfilzomib. ([`federal-register-2012-10154-49dd1da902a8`](#source-federal-register-2012-10154-49dd1da902a8))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2012-10154-49dd1da902a8`](#source-federal-register-2012-10154-49dd1da902a8))

### Sources

<a id="source-federal-register-2012-10154-49dd1da902a8"></a>
- **Federal Register notice 2012-10154 · published 2012-04-27 · Oncologic Drugs Advisory Committee; Notice of Meeting** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2012-04-27/pdf/2012-10154.pdf) (`federal-register-2012-10154-49dd1da902a8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2012-10154." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#federal-register-2012-10154-v1 SHA-256: 2418e27b7730cad00dc493f4ace3bafaca21d97df7c30e93a92a7d632d645571.

---

<a id="federal-register-2014-11175-v1"></a>

## Federal Register notice 2014-11175

> The Federal Register published notice 2014-11175, attributed to FDA and its parent HHS department, on 2014-05-15. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; KYPROLIS,” and PeptideScanner's exact reviewed identity mapping connects the document to Carfilzomib.

- Evidence object: `story:federal-register-2014-11175:v1`
- Evidence domain: Regulatory
- Date in source: 2014-05-15
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/federal-register-2014-11175/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#federal-register-2014-11175-v1
- Content SHA-256: `e31c06e64a911dd0d4688774ad7329d4d8b86b08da42d3c0d9e7c17306e7b8a8`

### Claims and source pins

#### Headline

Federal Register notice 2014-11175 ([`federal-register-2014-11175-238c199aa553`](#source-federal-register-2014-11175-238c199aa553))

#### Summary

The Federal Register published notice 2014-11175, attributed to FDA and its parent HHS department, on 2014-05-15. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; KYPROLIS,” and PeptideScanner's exact reviewed identity mapping connects the document to Carfilzomib. ([`federal-register-2014-11175-238c199aa553`](#source-federal-register-2014-11175-238c199aa553))

#### Paragraph 1

The Federal Register published notice 2014-11175, attributed to FDA and its parent HHS department, on 2014-05-15. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; KYPROLIS,” and PeptideScanner's exact reviewed identity mapping connects the document to Carfilzomib. ([`federal-register-2014-11175-238c199aa553`](#source-federal-register-2014-11175-238c199aa553))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2014-11175-238c199aa553`](#source-federal-register-2014-11175-238c199aa553))

### Sources

<a id="source-federal-register-2014-11175-238c199aa553"></a>
- **Federal Register notice 2014-11175 · published 2014-05-15 · Determination of Regulatory Review Period for Purposes of Patent Extension; KYPROLIS** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2014-05-15/pdf/2014-11175.pdf) (`federal-register-2014-11175-238c199aa553`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2014-11175." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#federal-register-2014-11175-v1 SHA-256: e31c06e64a911dd0d4688774ad7329d4d8b86b08da42d3c0d9e7c17306e7b8a8.

---

<a id="pubmed-pmid-34647444-carfilzomib-v1"></a>

## Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis.

> PubMed lists PMID 34647444 in Haematologica as Clinical Trial, Phase III, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-06-01 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-34647444-carfilzomib:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-34647444-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-34647444-carfilzomib-v1
- Content SHA-256: `5dd56e36251adaedc5bce66ef16384707e0ca7a535e876655659309436627579`

### Claims and source pins

#### Headline

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis. ([`pubmed-observation-pmid-34647444-2026-09-27-82cc0c95365f`](#source-pubmed-observation-pmid-34647444-2026-09-27-82cc0c95365f))

#### Summary

PubMed lists PMID 34647444 in Haematologica as Clinical Trial, Phase III, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-06-01 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34647444-2026-09-27-82cc0c95365f`](#source-pubmed-observation-pmid-34647444-2026-09-27-82cc0c95365f))

#### Paragraph 1

PubMed lists PMID 34647444 in Haematologica as Clinical Trial, Phase III, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-06-01 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34647444-2026-09-27-82cc0c95365f`](#source-pubmed-observation-pmid-34647444-2026-09-27-82cc0c95365f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-34647444-2026-09-27-82cc0c95365f`](#source-pubmed-observation-pmid-34647444-2026-09-27-82cc0c95365f))

### Sources

<a id="source-pubmed-observation-pmid-34647444-2026-09-27-82cc0c95365f"></a>
- **Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis. · retained source version 1:2026-09-27:current:82cc0c95365faaf7d3b6fcbf9472ff9b81a0b08f608d5af4aa29407ad76edeb3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/34647444/) (`pubmed-observation-pmid-34647444-2026-09-27-82cc0c95365f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-34647444-carfilzomib-v1 SHA-256: 5dd56e36251adaedc5bce66ef16384707e0ca7a535e876655659309436627579.

---

<a id="pubmed-pmid-34774221-carfilzomib-v1"></a>

## Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with…

> PubMed lists PMID 34774221 in The Lancet. Oncology as Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-11-11 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-34774221-carfilzomib:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-01-10
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-34774221-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-34774221-carfilzomib-v1
- Content SHA-256: `1278ff22fc308ce121d9ea7721a3e0afcb87a90326a28e622f2e79f4b47d69df`

### Claims and source pins

#### Headline

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with… ([`pubmed-observation-pmid-34774221-2022-01-10-239914252f2e`](#source-pubmed-observation-pmid-34774221-2022-01-10-239914252f2e))

#### Summary

PubMed lists PMID 34774221 in The Lancet. Oncology as Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-11-11 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34774221-2022-01-10-239914252f2e`](#source-pubmed-observation-pmid-34774221-2022-01-10-239914252f2e))

#### Paragraph 1

PubMed lists PMID 34774221 in The Lancet. Oncology as Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-11-11 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34774221-2022-01-10-239914252f2e`](#source-pubmed-observation-pmid-34774221-2022-01-10-239914252f2e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-34774221-2022-01-10-239914252f2e`](#source-pubmed-observation-pmid-34774221-2022-01-10-239914252f2e))

### Sources

<a id="source-pubmed-observation-pmid-34774221-2022-01-10-239914252f2e"></a>
- **Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. · retained source version 1:2022-01-10:current:239914252f2e0b78e00fd3b1d5b6dc6cc77385d5f4ca2ab146afda68b40b0a6d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/34774221/) (`pubmed-observation-pmid-34774221-2022-01-10-239914252f2e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with…." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-34774221-carfilzomib-v1 SHA-256: 1278ff22fc308ce121d9ea7721a3e0afcb87a90326a28e622f2e79f4b47d69df.

---

<a id="pubmed-pmid-35578151-carfilzomib-v1"></a>

## Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis.

> PubMed lists PMID 35578151 in International journal of hematology as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2022-05-17 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35578151-carfilzomib:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-29
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35578151-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-35578151-carfilzomib-v1
- Content SHA-256: `3da7d0f0a50f425ea1641c02841588f23642ffbd9a9905cd26249161d07b863f`

### Claims and source pins

#### Headline

Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis. ([`pubmed-observation-pmid-35578151-2026-10-29-2a939a3286e3`](#source-pubmed-observation-pmid-35578151-2026-10-29-2a939a3286e3))

#### Summary

PubMed lists PMID 35578151 in International journal of hematology as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2022-05-17 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35578151-2026-10-29-2a939a3286e3`](#source-pubmed-observation-pmid-35578151-2026-10-29-2a939a3286e3))

#### Paragraph 1

PubMed lists PMID 35578151 in International journal of hematology as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2022-05-17 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35578151-2026-10-29-2a939a3286e3`](#source-pubmed-observation-pmid-35578151-2026-10-29-2a939a3286e3))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35578151-2026-10-29-2a939a3286e3`](#source-pubmed-observation-pmid-35578151-2026-10-29-2a939a3286e3))

### Sources

<a id="source-pubmed-observation-pmid-35578151-2026-10-29-2a939a3286e3"></a>
- **Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis. · retained source version 1:2026-10-29:current:2a939a3286e3a5ee973e0307add4c75aff83149e6f34f04295c1f1f94632ad0a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35578151/) (`pubmed-observation-pmid-35578151-2026-10-29-2a939a3286e3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-35578151-carfilzomib-v1 SHA-256: 3da7d0f0a50f425ea1641c02841588f23642ffbd9a9905cd26249161d07b863f.

---

<a id="pubmed-pmid-36073950-carfilzomib-v1"></a>

## Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study.

> PubMed lists PMID 36073950 in Japanese journal of clinical oncology as Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-12-05 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36073950-carfilzomib:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36073950-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-36073950-carfilzomib-v1
- Content SHA-256: `e35b41541f612a5ed9b1b4c611d3da067fd63ec3b2ef3603bd4ab3cab7114842`

### Claims and source pins

#### Headline

Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study. ([`pubmed-observation-pmid-36073950-2026-01-27-e0ee6ab9444a`](#source-pubmed-observation-pmid-36073950-2026-01-27-e0ee6ab9444a))

#### Summary

PubMed lists PMID 36073950 in Japanese journal of clinical oncology as Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-12-05 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36073950-2026-01-27-e0ee6ab9444a`](#source-pubmed-observation-pmid-36073950-2026-01-27-e0ee6ab9444a))

#### Paragraph 1

PubMed lists PMID 36073950 in Japanese journal of clinical oncology as Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-12-05 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36073950-2026-01-27-e0ee6ab9444a`](#source-pubmed-observation-pmid-36073950-2026-01-27-e0ee6ab9444a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36073950-2026-01-27-e0ee6ab9444a`](#source-pubmed-observation-pmid-36073950-2026-01-27-e0ee6ab9444a))

### Sources

<a id="source-pubmed-observation-pmid-36073950-2026-01-27-e0ee6ab9444a"></a>
- **Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study. · retained source version 1:2026-01-27:current:e0ee6ab9444a45b0f13e211ea69a5d2fb65c5c733ec22dd039244fc1bbc93a82** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36073950/) (`pubmed-observation-pmid-36073950-2026-01-27-e0ee6ab9444a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-36073950-carfilzomib-v1 SHA-256: e35b41541f612a5ed9b1b4c611d3da067fd63ec3b2ef3603bd4ab3cab7114842.

---

<a id="pubmed-pmid-36372355-carfilzomib-v1"></a>

## Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation.

> PubMed lists PMID 36372355 in Transplantation and cellular therapy as Randomized Controlled Trial, Clinical Trial, Phase III, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-11-11 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36372355-carfilzomib:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36372355-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-36372355-carfilzomib-v1
- Content SHA-256: `766adbc2e9f70d044cb76f043719d062891ec5832da8920c83d79d5931c13031`

### Claims and source pins

#### Headline

Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation. ([`pubmed-observation-pmid-36372355-2026-01-27-143b9cf85c46`](#source-pubmed-observation-pmid-36372355-2026-01-27-143b9cf85c46))

#### Summary

PubMed lists PMID 36372355 in Transplantation and cellular therapy as Randomized Controlled Trial, Clinical Trial, Phase III, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-11-11 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36372355-2026-01-27-143b9cf85c46`](#source-pubmed-observation-pmid-36372355-2026-01-27-143b9cf85c46))

#### Paragraph 1

PubMed lists PMID 36372355 in Transplantation and cellular therapy as Randomized Controlled Trial, Clinical Trial, Phase III, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-11-11 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36372355-2026-01-27-143b9cf85c46`](#source-pubmed-observation-pmid-36372355-2026-01-27-143b9cf85c46))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36372355-2026-01-27-143b9cf85c46`](#source-pubmed-observation-pmid-36372355-2026-01-27-143b9cf85c46))

### Sources

<a id="source-pubmed-observation-pmid-36372355-2026-01-27-143b9cf85c46"></a>
- **Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation. · retained source version 1:2026-01-27:current:143b9cf85c4670f4bda82606cab58343ab5f687f2f68406c0e9e617fd6b7b1d0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36372355/) (`pubmed-observation-pmid-36372355-2026-01-27-143b9cf85c46`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-36372355-carfilzomib-v1 SHA-256: 766adbc2e9f70d044cb76f043719d062891ec5832da8920c83d79d5931c13031.

---

<a id="pubmed-pmid-36375132-carfilzomib-v1"></a>

## Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL.

> PubMed lists PMID 36375132 in Blood advances as Clinical Trial, Phase I, Journal Article, with publication-date metadata of 2023-04-11 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36375132-carfilzomib:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36375132-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-36375132-carfilzomib-v1
- Content SHA-256: `5e0eb4572e5c523943bb7c405c7b3d141a1a4d2482fe8aaaa162c5370862fe00`

### Claims and source pins

#### Headline

Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL. ([`pubmed-observation-pmid-36375132-2026-01-27-e38494a598b3`](#source-pubmed-observation-pmid-36375132-2026-01-27-e38494a598b3))

#### Summary

PubMed lists PMID 36375132 in Blood advances as Clinical Trial, Phase I, Journal Article, with publication-date metadata of 2023-04-11 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36375132-2026-01-27-e38494a598b3`](#source-pubmed-observation-pmid-36375132-2026-01-27-e38494a598b3))

#### Paragraph 1

PubMed lists PMID 36375132 in Blood advances as Clinical Trial, Phase I, Journal Article, with publication-date metadata of 2023-04-11 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36375132-2026-01-27-e38494a598b3`](#source-pubmed-observation-pmid-36375132-2026-01-27-e38494a598b3))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36375132-2026-01-27-e38494a598b3`](#source-pubmed-observation-pmid-36375132-2026-01-27-e38494a598b3))

### Sources

<a id="source-pubmed-observation-pmid-36375132-2026-01-27-e38494a598b3"></a>
- **Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL. · retained source version 1:2026-01-27:current:e38494a598b3d1806034fb75e9893fae274e3d588d9ef8ed9cfd9230202f623e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36375132/) (`pubmed-observation-pmid-36375132-2026-01-27-e38494a598b3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-36375132-carfilzomib-v1 SHA-256: 5e0eb4572e5c523943bb7c405c7b3d141a1a4d2482fe8aaaa162c5370862fe00.

---

<a id="pubmed-pmid-36529145-carfilzomib-v1"></a>

## Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myel…

> PubMed lists PMID 36529145 in The Lancet. Haematology as Clinical Trial, Phase II, Equivalence Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2022-12-15 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36529145-carfilzomib:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36529145-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-36529145-carfilzomib-v1
- Content SHA-256: `fc1cd7155b0c14120fbfbad9119d69d35fb30147389d1692e6c87576f6b71644`

### Claims and source pins

#### Headline

Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myel… ([`pubmed-observation-pmid-36529145-2026-11-09-9096c5c964d0`](#source-pubmed-observation-pmid-36529145-2026-11-09-9096c5c964d0))

#### Summary

PubMed lists PMID 36529145 in The Lancet. Haematology as Clinical Trial, Phase II, Equivalence Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2022-12-15 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36529145-2026-11-09-9096c5c964d0`](#source-pubmed-observation-pmid-36529145-2026-11-09-9096c5c964d0))

#### Paragraph 1

PubMed lists PMID 36529145 in The Lancet. Haematology as Clinical Trial, Phase II, Equivalence Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 2022-12-15 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36529145-2026-11-09-9096c5c964d0`](#source-pubmed-observation-pmid-36529145-2026-11-09-9096c5c964d0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36529145-2026-11-09-9096c5c964d0`](#source-pubmed-observation-pmid-36529145-2026-11-09-9096c5c964d0))

### Sources

<a id="source-pubmed-observation-pmid-36529145-2026-11-09-9096c5c964d0"></a>
- **Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial. · retained source version 1:2026-11-09:current:9096c5c964d081bd18a6344ac479255bd3ae15f02d421509ac6104af90efd28b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36529145/) (`pubmed-observation-pmid-36529145-2026-11-09-9096c5c964d0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myel…." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-36529145-carfilzomib-v1 SHA-256: fc1cd7155b0c14120fbfbad9119d69d35fb30147389d1692e6c87576f6b71644.

---

<a id="pubmed-pmid-36642080-carfilzomib-v1"></a>

## Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a r…

> PubMed lists PMID 36642080 in The Lancet. Oncology as Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase III, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-01-12 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36642080-carfilzomib:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36642080-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-36642080-carfilzomib-v1
- Content SHA-256: `60d3db81432499949a3ea7431b12c2e71942b35a745d56149e6c24f3c2d8744a`

### Claims and source pins

#### Headline

Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a r… ([`pubmed-observation-pmid-36642080-2026-01-27-4c1643a302c0`](#source-pubmed-observation-pmid-36642080-2026-01-27-4c1643a302c0))

#### Summary

PubMed lists PMID 36642080 in The Lancet. Oncology as Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase III, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-01-12 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36642080-2026-01-27-4c1643a302c0`](#source-pubmed-observation-pmid-36642080-2026-01-27-4c1643a302c0))

#### Paragraph 1

PubMed lists PMID 36642080 in The Lancet. Oncology as Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase III, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-01-12 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36642080-2026-01-27-4c1643a302c0`](#source-pubmed-observation-pmid-36642080-2026-01-27-4c1643a302c0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36642080-2026-01-27-4c1643a302c0`](#source-pubmed-observation-pmid-36642080-2026-01-27-4c1643a302c0))

### Sources

<a id="source-pubmed-observation-pmid-36642080-2026-01-27-4c1643a302c0"></a>
- **Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. · retained source version 1:2026-01-27:current:4c1643a302c0f0b15a5559eeb811fad050baeb1ffac5667ecf20270fa70b9bcb** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36642080/) (`pubmed-observation-pmid-36642080-2026-01-27-4c1643a302c0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a r…." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-36642080-carfilzomib-v1 SHA-256: 60d3db81432499949a3ea7431b12c2e71942b35a745d56149e6c24f3c2d8744a.

---

<a id="pubmed-pmid-36763537-carfilzomib-v1"></a>

## Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma.

> PubMed lists PMID 36763537 in Blood advances as Clinical Trial, Phase II, Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-10-10 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36763537-carfilzomib:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36763537-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-36763537-carfilzomib-v1
- Content SHA-256: `bf63295274c789197f381dc85ed8f3d5c7f9ddb11f516b0485f370ba2e59cdd1`

### Claims and source pins

#### Headline

Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma. ([`pubmed-observation-pmid-36763537-2026-01-27-9a399cce3d36`](#source-pubmed-observation-pmid-36763537-2026-01-27-9a399cce3d36))

#### Summary

PubMed lists PMID 36763537 in Blood advances as Clinical Trial, Phase II, Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-10-10 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36763537-2026-01-27-9a399cce3d36`](#source-pubmed-observation-pmid-36763537-2026-01-27-9a399cce3d36))

#### Paragraph 1

PubMed lists PMID 36763537 in Blood advances as Clinical Trial, Phase II, Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-10-10 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36763537-2026-01-27-9a399cce3d36`](#source-pubmed-observation-pmid-36763537-2026-01-27-9a399cce3d36))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36763537-2026-01-27-9a399cce3d36`](#source-pubmed-observation-pmid-36763537-2026-01-27-9a399cce3d36))

### Sources

<a id="source-pubmed-observation-pmid-36763537-2026-01-27-9a399cce3d36"></a>
- **Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma. · retained source version 1:2026-01-27:current:9a399cce3d3654a6c0b98f8f0d3d5f17dd484548dfd7cb3dc2e6bb3ad67c9bec** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36763537/) (`pubmed-observation-pmid-36763537-2026-01-27-9a399cce3d36`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-36763537-carfilzomib-v1 SHA-256: bf63295274c789197f381dc85ed8f3d5c7f9ddb11f516b0485f370ba2e59cdd1.

---

<a id="pubmed-pmid-37479547-carfilzomib-v1"></a>

## Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis.

> PubMed lists PMID 37479547 in Clinical lymphoma, myeloma & leukemia as Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-07-03 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37479547-carfilzomib:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37479547-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-37479547-carfilzomib-v1
- Content SHA-256: `ea78ba796121cb5cbd5685567bb8042c8a411947a4208d7775c8bbca31956afb`

### Claims and source pins

#### Headline

Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis. ([`pubmed-observation-pmid-37479547-2026-01-27-7b75017f7026`](#source-pubmed-observation-pmid-37479547-2026-01-27-7b75017f7026))

#### Summary

PubMed lists PMID 37479547 in Clinical lymphoma, myeloma & leukemia as Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-07-03 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37479547-2026-01-27-7b75017f7026`](#source-pubmed-observation-pmid-37479547-2026-01-27-7b75017f7026))

#### Paragraph 1

PubMed lists PMID 37479547 in Clinical lymphoma, myeloma & leukemia as Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-07-03 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37479547-2026-01-27-7b75017f7026`](#source-pubmed-observation-pmid-37479547-2026-01-27-7b75017f7026))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37479547-2026-01-27-7b75017f7026`](#source-pubmed-observation-pmid-37479547-2026-01-27-7b75017f7026))

### Sources

<a id="source-pubmed-observation-pmid-37479547-2026-01-27-7b75017f7026"></a>
- **Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis. · retained source version 1:2026-01-27:current:7b75017f7026100b9d19d460c0fa77e423e7b04a8794420529a99be8156f1905** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37479547/) (`pubmed-observation-pmid-37479547-2026-01-27-7b75017f7026`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-37479547-carfilzomib-v1 SHA-256: ea78ba796121cb5cbd5685567bb8042c8a411947a4208d7775c8bbca31956afb.

---

<a id="pubmed-pmid-37584290-carfilzomib-v1"></a>

## Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis.

> PubMed lists PMID 37584290 in Haematologica as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-02-01 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37584290-carfilzomib:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-10-23
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37584290-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-37584290-carfilzomib-v1
- Content SHA-256: `b0e854055eb75138ec10822b93bcc72182574207a7af0fc0a636d8b48a2c62b5`

### Claims and source pins

#### Headline

Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis. ([`pubmed-observation-pmid-37584290-2024-10-23-d556839a15af`](#source-pubmed-observation-pmid-37584290-2024-10-23-d556839a15af))

#### Summary

PubMed lists PMID 37584290 in Haematologica as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-02-01 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37584290-2024-10-23-d556839a15af`](#source-pubmed-observation-pmid-37584290-2024-10-23-d556839a15af))

#### Paragraph 1

PubMed lists PMID 37584290 in Haematologica as Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-02-01 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37584290-2024-10-23-d556839a15af`](#source-pubmed-observation-pmid-37584290-2024-10-23-d556839a15af))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37584290-2024-10-23-d556839a15af`](#source-pubmed-observation-pmid-37584290-2024-10-23-d556839a15af))

### Sources

<a id="source-pubmed-observation-pmid-37584290-2024-10-23-d556839a15af"></a>
- **Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis. · retained source version 1:2024-10-23:current:d556839a15af49afa5bb0c5caab8fe34f9c0d114967d8fb373ad2bc760384456** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37584290/) (`pubmed-observation-pmid-37584290-2024-10-23-d556839a15af`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-37584290-carfilzomib-v1 SHA-256: b0e854055eb75138ec10822b93bcc72182574207a7af0fc0a636d8b48a2c62b5.

---

<a id="pubmed-pmid-37632592-carfilzomib-v1"></a>

## Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell L…

> PubMed lists PMID 37632592 in Targeted oncology as Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-08-26 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37632592-carfilzomib:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37632592-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-37632592-carfilzomib-v1
- Content SHA-256: `b61f89ae58b535b312c17e58fb71227e5268c2da0a0606dfde3885d09d36fb09`

### Claims and source pins

#### Headline

Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell L… ([`pubmed-observation-pmid-37632592-2026-01-27-b376aecb1839`](#source-pubmed-observation-pmid-37632592-2026-01-27-b376aecb1839))

#### Summary

PubMed lists PMID 37632592 in Targeted oncology as Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-08-26 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37632592-2026-01-27-b376aecb1839`](#source-pubmed-observation-pmid-37632592-2026-01-27-b376aecb1839))

#### Paragraph 1

PubMed lists PMID 37632592 in Targeted oncology as Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-08-26 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37632592-2026-01-27-b376aecb1839`](#source-pubmed-observation-pmid-37632592-2026-01-27-b376aecb1839))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37632592-2026-01-27-b376aecb1839`](#source-pubmed-observation-pmid-37632592-2026-01-27-b376aecb1839))

### Sources

<a id="source-pubmed-observation-pmid-37632592-2026-01-27-b376aecb1839"></a>
- **Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. · retained source version 1:2026-01-27:current:b376aecb18397a324d83b10f02e93f1e2092506e0a949b9f9c308edc3afe6c13** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37632592/) (`pubmed-observation-pmid-37632592-2026-01-27-b376aecb1839`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell L…." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-37632592-carfilzomib-v1 SHA-256: b61f89ae58b535b312c17e58fb71227e5268c2da0a0606dfde3885d09d36fb09.

---

<a id="pubmed-pmid-37691005-carfilzomib-v1"></a>

## Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomi…

> PubMed lists PMID 37691005 in British journal of haematology as Clinical Trial, Phase III, Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-09-10 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37691005-carfilzomib:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37691005-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-37691005-carfilzomib-v1
- Content SHA-256: `9f8558cba04e8b9fb91a55933b5e06e092ae7003c43f121317544a1f3012edca`

### Claims and source pins

#### Headline

Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomi… ([`pubmed-observation-pmid-37691005-2026-01-27-f5ec248a9735`](#source-pubmed-observation-pmid-37691005-2026-01-27-f5ec248a9735))

#### Summary

PubMed lists PMID 37691005 in British journal of haematology as Clinical Trial, Phase III, Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-09-10 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37691005-2026-01-27-f5ec248a9735`](#source-pubmed-observation-pmid-37691005-2026-01-27-f5ec248a9735))

#### Paragraph 1

PubMed lists PMID 37691005 in British journal of haematology as Clinical Trial, Phase III, Randomized Controlled Trial, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-09-10 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37691005-2026-01-27-f5ec248a9735`](#source-pubmed-observation-pmid-37691005-2026-01-27-f5ec248a9735))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37691005-2026-01-27-f5ec248a9735`](#source-pubmed-observation-pmid-37691005-2026-01-27-f5ec248a9735))

### Sources

<a id="source-pubmed-observation-pmid-37691005-2026-01-27-f5ec248a9735"></a>
- **Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial. · retained source version 1:2026-01-27:current:f5ec248a9735aa9ea93965d7f70ad7314de30d8b2401eecae55eb7aec626fd04** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37691005/) (`pubmed-observation-pmid-37691005-2026-01-27-f5ec248a9735`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomi…." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-37691005-carfilzomib-v1 SHA-256: 9f8558cba04e8b9fb91a55933b5e06e092ae7003c43f121317544a1f3012edca.

---

<a id="pubmed-pmid-37717583-carfilzomib-v1"></a>

## Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study.

> PubMed lists PMID 37717583 in The Lancet. Oncology as Journal Article, Multicenter Study, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-09-14 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37717583-carfilzomib:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-03-24
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37717583-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-37717583-carfilzomib-v1
- Content SHA-256: `184646cb29baa4345741d075a546021f3b53b771d304f322dd0770d27b9c15fa`

### Claims and source pins

#### Headline

Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study. ([`pubmed-observation-pmid-37717583-2026-03-24-9fa19db13ff5`](#source-pubmed-observation-pmid-37717583-2026-03-24-9fa19db13ff5))

#### Summary

PubMed lists PMID 37717583 in The Lancet. Oncology as Journal Article, Multicenter Study, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-09-14 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37717583-2026-03-24-9fa19db13ff5`](#source-pubmed-observation-pmid-37717583-2026-03-24-9fa19db13ff5))

#### Paragraph 1

PubMed lists PMID 37717583 in The Lancet. Oncology as Journal Article, Multicenter Study, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-09-14 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37717583-2026-03-24-9fa19db13ff5`](#source-pubmed-observation-pmid-37717583-2026-03-24-9fa19db13ff5))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37717583-2026-03-24-9fa19db13ff5`](#source-pubmed-observation-pmid-37717583-2026-03-24-9fa19db13ff5))

### Sources

<a id="source-pubmed-observation-pmid-37717583-2026-03-24-9fa19db13ff5"></a>
- **Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study. · retained source version 1:2026-03-24:current:9fa19db13ff515bceed9c0ce6b531128642090c45badd573447b730a80714207** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37717583/) (`pubmed-observation-pmid-37717583-2026-03-24-9fa19db13ff5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-37717583-carfilzomib-v1 SHA-256: 184646cb29baa4345741d075a546021f3b53b771d304f322dd0770d27b9c15fa.

---

<a id="pubmed-pmid-38747414-carfilzomib-v1"></a>

## Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide al…

> PubMed lists PMID 38747414 in Polish archives of internal medicine as Journal Article, Clinical Trial, Phase III, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-05-14 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38747414-carfilzomib:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-09-14
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38747414-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-38747414-carfilzomib-v1
- Content SHA-256: `434ee580f007a9a4c5f694fb35da2548e20039a34158de0ae1dfc715f3b49ef8`

### Claims and source pins

#### Headline

Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide al… ([`pubmed-observation-pmid-38747414-2024-09-14-f9d9445b67da`](#source-pubmed-observation-pmid-38747414-2024-09-14-f9d9445b67da))

#### Summary

PubMed lists PMID 38747414 in Polish archives of internal medicine as Journal Article, Clinical Trial, Phase III, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-05-14 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38747414-2024-09-14-f9d9445b67da`](#source-pubmed-observation-pmid-38747414-2024-09-14-f9d9445b67da))

#### Paragraph 1

PubMed lists PMID 38747414 in Polish archives of internal medicine as Journal Article, Clinical Trial, Phase III, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-05-14 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38747414-2024-09-14-f9d9445b67da`](#source-pubmed-observation-pmid-38747414-2024-09-14-f9d9445b67da))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38747414-2024-09-14-f9d9445b67da`](#source-pubmed-observation-pmid-38747414-2024-09-14-f9d9445b67da))

### Sources

<a id="source-pubmed-observation-pmid-38747414-2024-09-14-f9d9445b67da"></a>
- **Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone. · retained source version 1:2024-09-14:current:f9d9445b67daa2f97e3f331af000ff622ebb30d08a2d82fa490b692ebe31f3bf** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38747414/) (`pubmed-observation-pmid-38747414-2024-09-14-f9d9445b67da`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide al…." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-38747414-carfilzomib-v1 SHA-256: 434ee580f007a9a4c5f694fb35da2548e20039a34158de0ae1dfc715f3b49ef8.

---

<a id="pubmed-pmid-38811560-carfilzomib-v1"></a>

## Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant.

> PubMed lists PMID 38811560 in Blood cancer journal as Journal Article, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-05-29 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38811560-carfilzomib:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-11-07
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38811560-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-38811560-carfilzomib-v1
- Content SHA-256: `92f82085eedef61f45057c7a0b8e5298e448acbbcb44314c7ed93148aece56a1`

### Claims and source pins

#### Headline

Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant. ([`pubmed-observation-pmid-38811560-2024-11-07-c4a7896494bf`](#source-pubmed-observation-pmid-38811560-2024-11-07-c4a7896494bf))

#### Summary

PubMed lists PMID 38811560 in Blood cancer journal as Journal Article, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-05-29 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38811560-2024-11-07-c4a7896494bf`](#source-pubmed-observation-pmid-38811560-2024-11-07-c4a7896494bf))

#### Paragraph 1

PubMed lists PMID 38811560 in Blood cancer journal as Journal Article, Clinical Trial, Phase II, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-05-29 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38811560-2024-11-07-c4a7896494bf`](#source-pubmed-observation-pmid-38811560-2024-11-07-c4a7896494bf))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38811560-2024-11-07-c4a7896494bf`](#source-pubmed-observation-pmid-38811560-2024-11-07-c4a7896494bf))

### Sources

<a id="source-pubmed-observation-pmid-38811560-2024-11-07-c4a7896494bf"></a>
- **Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant. · retained source version 1:2024-11-07:current:c4a7896494bf9a2ac033103564279f7d4ed2a69dfe876b43876b53dd17a7533c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38811560/) (`pubmed-observation-pmid-38811560-2024-11-07-c4a7896494bf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-38811560-carfilzomib-v1 SHA-256: 92f82085eedef61f45057c7a0b8e5298e448acbbcb44314c7ed93148aece56a1.

---

<a id="pubmed-pmid-38938122-carfilzomib-v1"></a>

## Carfilzomib, lenalidomide, dexamethasone (KRD) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi.

> PubMed lists PMID 38938122 in British journal of haematology as Journal Article, Clinical Trial, Phase II, Multicenter Study, with publication-date metadata of 2024-06-28 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38938122-carfilzomib:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-01-30
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38938122-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-38938122-carfilzomib-v1
- Content SHA-256: `c1a51c126c50acf91af1932d4c54878010df0cae6fdb3f34d6569fd949067a95`

### Claims and source pins

#### Headline

Carfilzomib, lenalidomide, dexamethasone (KRD) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi. ([`pubmed-observation-pmid-38938122-2025-01-30-95bddc1e47d2`](#source-pubmed-observation-pmid-38938122-2025-01-30-95bddc1e47d2))

#### Summary

PubMed lists PMID 38938122 in British journal of haematology as Journal Article, Clinical Trial, Phase II, Multicenter Study, with publication-date metadata of 2024-06-28 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38938122-2025-01-30-95bddc1e47d2`](#source-pubmed-observation-pmid-38938122-2025-01-30-95bddc1e47d2))

#### Paragraph 1

PubMed lists PMID 38938122 in British journal of haematology as Journal Article, Clinical Trial, Phase II, Multicenter Study, with publication-date metadata of 2024-06-28 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38938122-2025-01-30-95bddc1e47d2`](#source-pubmed-observation-pmid-38938122-2025-01-30-95bddc1e47d2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38938122-2025-01-30-95bddc1e47d2`](#source-pubmed-observation-pmid-38938122-2025-01-30-95bddc1e47d2))

### Sources

<a id="source-pubmed-observation-pmid-38938122-2025-01-30-95bddc1e47d2"></a>
- **Carfilzomib, lenalidomide, dexamethasone (KRD) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi. · retained source version 1:2025-01-30:current:95bddc1e47d276c079b4c87ef4b3181b1625a68cd150868b6f95297897f8faf6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38938122/) (`pubmed-observation-pmid-38938122-2025-01-30-95bddc1e47d2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Carfilzomib, lenalidomide, dexamethasone (KRD) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-38938122-carfilzomib-v1 SHA-256: c1a51c126c50acf91af1932d4c54878010df0cae6fdb3f34d6569fd949067a95.

---

<a id="pubmed-pmid-39576965-carfilzomib-v1"></a>

## MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma.

> PubMed lists PMID 39576965 in Blood advances as Journal Article, Clinical Trial, Phase II, with publication-date metadata of 2025-02-11 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39576965-carfilzomib:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-06-03
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39576965-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-39576965-carfilzomib-v1
- Content SHA-256: `01c2a2ffd52c7cb8ae90c65dffdebbc8c23bdc2d548c204254d17c82ff0311bc`

### Claims and source pins

#### Headline

MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma. ([`pubmed-observation-pmid-39576965-2025-06-03-abf9232455d8`](#source-pubmed-observation-pmid-39576965-2025-06-03-abf9232455d8))

#### Summary

PubMed lists PMID 39576965 in Blood advances as Journal Article, Clinical Trial, Phase II, with publication-date metadata of 2025-02-11 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39576965-2025-06-03-abf9232455d8`](#source-pubmed-observation-pmid-39576965-2025-06-03-abf9232455d8))

#### Paragraph 1

PubMed lists PMID 39576965 in Blood advances as Journal Article, Clinical Trial, Phase II, with publication-date metadata of 2025-02-11 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39576965-2025-06-03-abf9232455d8`](#source-pubmed-observation-pmid-39576965-2025-06-03-abf9232455d8))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39576965-2025-06-03-abf9232455d8`](#source-pubmed-observation-pmid-39576965-2025-06-03-abf9232455d8))

### Sources

<a id="source-pubmed-observation-pmid-39576965-2025-06-03-abf9232455d8"></a>
- **MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma. · retained source version 1:2025-06-03:current:abf9232455d8616e97784c0a8c9d2739f8d04b4b91331e8ea523c025aa93d30c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39576965/) (`pubmed-observation-pmid-39576965-2025-06-03-abf9232455d8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-39576965-carfilzomib-v1 SHA-256: 01c2a2ffd52c7cb8ae90c65dffdebbc8c23bdc2d548c204254d17c82ff0311bc.

---

<a id="pubmed-pmid-39638553-carfilzomib-v1"></a>

## Health-Related Quality of Life During Carfilzomib-Lenalidomide-Dexamethasone Consolidation: Findings From the Multiple Myeloma CONPET Study.

> PubMed lists PMID 39638553 in European journal of haematology as Clinical Trial, Phase II, Journal Article, Multicenter Study, with publication-date metadata of 2024-12-05 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39638553-carfilzomib:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-06-05
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39638553-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-39638553-carfilzomib-v1
- Content SHA-256: `88d3482e39f28d20766a97955f37b3704e0c266e936b1578a992c25b9b890279`

### Claims and source pins

#### Headline

Health-Related Quality of Life During Carfilzomib-Lenalidomide-Dexamethasone Consolidation: Findings From the Multiple Myeloma CONPET Study. ([`pubmed-observation-pmid-39638553-2025-06-05-ec85659e6675`](#source-pubmed-observation-pmid-39638553-2025-06-05-ec85659e6675))

#### Summary

PubMed lists PMID 39638553 in European journal of haematology as Clinical Trial, Phase II, Journal Article, Multicenter Study, with publication-date metadata of 2024-12-05 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39638553-2025-06-05-ec85659e6675`](#source-pubmed-observation-pmid-39638553-2025-06-05-ec85659e6675))

#### Paragraph 1

PubMed lists PMID 39638553 in European journal of haematology as Clinical Trial, Phase II, Journal Article, Multicenter Study, with publication-date metadata of 2024-12-05 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39638553-2025-06-05-ec85659e6675`](#source-pubmed-observation-pmid-39638553-2025-06-05-ec85659e6675))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39638553-2025-06-05-ec85659e6675`](#source-pubmed-observation-pmid-39638553-2025-06-05-ec85659e6675))

### Sources

<a id="source-pubmed-observation-pmid-39638553-2025-06-05-ec85659e6675"></a>
- **Health-Related Quality of Life During Carfilzomib-Lenalidomide-Dexamethasone Consolidation: Findings From the Multiple Myeloma CONPET Study. · retained source version 1:2025-06-05:current:ec85659e66757b19a3a373aba15017703280dab0356437a1992a45482443a822** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39638553/) (`pubmed-observation-pmid-39638553-2025-06-05-ec85659e6675`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Health-Related Quality of Life During Carfilzomib-Lenalidomide-Dexamethasone Consolidation: Findings From the Multiple Myeloma CONPET Study." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-39638553-carfilzomib-v1 SHA-256: 88d3482e39f28d20766a97955f37b3704e0c266e936b1578a992c25b9b890279.

---

<a id="pubmed-pmid-40213696-carfilzomib-v1"></a>

## Carfilzomib in multiple myeloma: unraveling cardiac toxicities - from mechanisms to diagnosis and management.

> PubMed lists PMID 40213696 in Frontiers in pharmacology as Journal Article, Review, with publication-date metadata of 2025-03-27 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40213696-carfilzomib:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-04-12
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40213696-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-40213696-carfilzomib-v1
- Content SHA-256: `6c39d2d78348eb444a2a23708bdccfd8b33366b776d296654843e5d9a653ff80`

### Claims and source pins

#### Headline

Carfilzomib in multiple myeloma: unraveling cardiac toxicities - from mechanisms to diagnosis and management. ([`pubmed-observation-pmid-40213696-2025-04-12-88f62ee9a362`](#source-pubmed-observation-pmid-40213696-2025-04-12-88f62ee9a362))

#### Summary

PubMed lists PMID 40213696 in Frontiers in pharmacology as Journal Article, Review, with publication-date metadata of 2025-03-27 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40213696-2025-04-12-88f62ee9a362`](#source-pubmed-observation-pmid-40213696-2025-04-12-88f62ee9a362))

#### Paragraph 1

PubMed lists PMID 40213696 in Frontiers in pharmacology as Journal Article, Review, with publication-date metadata of 2025-03-27 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40213696-2025-04-12-88f62ee9a362`](#source-pubmed-observation-pmid-40213696-2025-04-12-88f62ee9a362))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40213696-2025-04-12-88f62ee9a362`](#source-pubmed-observation-pmid-40213696-2025-04-12-88f62ee9a362))

### Sources

<a id="source-pubmed-observation-pmid-40213696-2025-04-12-88f62ee9a362"></a>
- **Carfilzomib in multiple myeloma: unraveling cardiac toxicities - from mechanisms to diagnosis and management. · retained source version 1:2025-04-12:current:88f62ee9a3623872119619aae9c4e60c6bff8823f5d3290e07ef941feb3b28f1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40213696/) (`pubmed-observation-pmid-40213696-2025-04-12-88f62ee9a362`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Carfilzomib in multiple myeloma: unraveling cardiac toxicities - from mechanisms to diagnosis and management." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-40213696-carfilzomib-v1 SHA-256: 6c39d2d78348eb444a2a23708bdccfd8b33366b776d296654843e5d9a653ff80.

---

<a id="pubmed-pmid-40397818-carfilzomib-v1"></a>

## Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study.

> PubMed lists PMID 40397818 in Leukemia & lymphoma as Journal Article, Clinical Trial, Phase II, Multicenter Study, Clinical Trial, Phase I, with publication-date metadata of 2025-05-21 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40397818-carfilzomib:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40397818-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-40397818-carfilzomib-v1
- Content SHA-256: `3a7790274ac6e40beafde3ef3a52bfe095da96ff92e5e539b8e90fdbb8220f55`

### Claims and source pins

#### Headline

Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study. ([`pubmed-observation-pmid-40397818-2026-11-13-88a3f6f3b812`](#source-pubmed-observation-pmid-40397818-2026-11-13-88a3f6f3b812))

#### Summary

PubMed lists PMID 40397818 in Leukemia & lymphoma as Journal Article, Clinical Trial, Phase II, Multicenter Study, Clinical Trial, Phase I, with publication-date metadata of 2025-05-21 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40397818-2026-11-13-88a3f6f3b812`](#source-pubmed-observation-pmid-40397818-2026-11-13-88a3f6f3b812))

#### Paragraph 1

PubMed lists PMID 40397818 in Leukemia & lymphoma as Journal Article, Clinical Trial, Phase II, Multicenter Study, Clinical Trial, Phase I, with publication-date metadata of 2025-05-21 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40397818-2026-11-13-88a3f6f3b812`](#source-pubmed-observation-pmid-40397818-2026-11-13-88a3f6f3b812))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40397818-2026-11-13-88a3f6f3b812`](#source-pubmed-observation-pmid-40397818-2026-11-13-88a3f6f3b812))

### Sources

<a id="source-pubmed-observation-pmid-40397818-2026-11-13-88a3f6f3b812"></a>
- **Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study. · retained source version 1:2026-11-13:current:88a3f6f3b812375c4f71c62f26ad40fc1057ca83c817126d5a97660548fde8f6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40397818/) (`pubmed-observation-pmid-40397818-2026-11-13-88a3f6f3b812`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-40397818-carfilzomib-v1 SHA-256: 3a7790274ac6e40beafde3ef3a52bfe095da96ff92e5e539b8e90fdbb8220f55.

---

<a id="pubmed-pmid-40672881-carfilzomib-v1"></a>

## Current and future role of carfilzomib-based quadruplet combinations as therapy for newly diagnosed multiple myeloma.

> PubMed lists PMID 40672881 in HemaSphere as Journal Article, Review, with publication-date metadata of 2025-07-16 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40672881-carfilzomib:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-09-06
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40672881-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-40672881-carfilzomib-v1
- Content SHA-256: `d3c972d9b4029e1b47f650cf75dbc95a61b9644b3b1b337baa0c4098522c1c6b`

### Claims and source pins

#### Headline

Current and future role of carfilzomib-based quadruplet combinations as therapy for newly diagnosed multiple myeloma. ([`pubmed-observation-pmid-40672881-2025-09-06-35ed90fc6803`](#source-pubmed-observation-pmid-40672881-2025-09-06-35ed90fc6803))

#### Summary

PubMed lists PMID 40672881 in HemaSphere as Journal Article, Review, with publication-date metadata of 2025-07-16 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40672881-2025-09-06-35ed90fc6803`](#source-pubmed-observation-pmid-40672881-2025-09-06-35ed90fc6803))

#### Paragraph 1

PubMed lists PMID 40672881 in HemaSphere as Journal Article, Review, with publication-date metadata of 2025-07-16 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40672881-2025-09-06-35ed90fc6803`](#source-pubmed-observation-pmid-40672881-2025-09-06-35ed90fc6803))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40672881-2025-09-06-35ed90fc6803`](#source-pubmed-observation-pmid-40672881-2025-09-06-35ed90fc6803))

### Sources

<a id="source-pubmed-observation-pmid-40672881-2025-09-06-35ed90fc6803"></a>
- **Current and future role of carfilzomib-based quadruplet combinations as therapy for newly diagnosed multiple myeloma. · retained source version 1:2025-09-06:current:35ed90fc6803dbf0ab02333a899744e05738178732f47ea83a55f8cfe33dcc65** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40672881/) (`pubmed-observation-pmid-40672881-2025-09-06-35ed90fc6803`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Current and future role of carfilzomib-based quadruplet combinations as therapy for newly diagnosed multiple myeloma." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-40672881-carfilzomib-v1 SHA-256: d3c972d9b4029e1b47f650cf75dbc95a61b9644b3b1b337baa0c4098522c1c6b.

---

<a id="pubmed-pmid-41134506-carfilzomib-v1"></a>

## Carfilzomib, pomalidomide, and dexamethasone for multiple myeloma after carfilzomib, lenalidomide, and dexamethasone.

> PubMed lists PMID 41134506 in International journal of hematology as Journal Article, Clinical Trial, Phase II, with publication-date metadata of 2025-10-24 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41134506-carfilzomib:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41134506-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-41134506-carfilzomib-v1
- Content SHA-256: `44d6021079736ca2e392e1b449b7b9bf8eb2801b5827b551fafdf2f94007eea5`

### Claims and source pins

#### Headline

Carfilzomib, pomalidomide, and dexamethasone for multiple myeloma after carfilzomib, lenalidomide, and dexamethasone. ([`pubmed-observation-pmid-41134506-2026-10-09-709434a09762`](#source-pubmed-observation-pmid-41134506-2026-10-09-709434a09762))

#### Summary

PubMed lists PMID 41134506 in International journal of hematology as Journal Article, Clinical Trial, Phase II, with publication-date metadata of 2025-10-24 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41134506-2026-10-09-709434a09762`](#source-pubmed-observation-pmid-41134506-2026-10-09-709434a09762))

#### Paragraph 1

PubMed lists PMID 41134506 in International journal of hematology as Journal Article, Clinical Trial, Phase II, with publication-date metadata of 2025-10-24 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41134506-2026-10-09-709434a09762`](#source-pubmed-observation-pmid-41134506-2026-10-09-709434a09762))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41134506-2026-10-09-709434a09762`](#source-pubmed-observation-pmid-41134506-2026-10-09-709434a09762))

### Sources

<a id="source-pubmed-observation-pmid-41134506-2026-10-09-709434a09762"></a>
- **Carfilzomib, pomalidomide, and dexamethasone for multiple myeloma after carfilzomib, lenalidomide, and dexamethasone. · retained source version 1:2026-10-09:current:709434a097623c12f1f75ba308c5af0d70edc4c75c881f86db2d0efad972b51c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41134506/) (`pubmed-observation-pmid-41134506-2026-10-09-709434a09762`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Carfilzomib, pomalidomide, and dexamethasone for multiple myeloma after carfilzomib, lenalidomide, and dexamethasone." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-41134506-carfilzomib-v1 SHA-256: 44d6021079736ca2e392e1b449b7b9bf8eb2801b5827b551fafdf2f94007eea5.

---

<a id="pubmed-pmid-41719502-carfilzomib-v1"></a>

## Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma.

> PubMed lists PMID 41719502 in Blood advances as Journal Article, Clinical Trial, Phase II, Clinical Trial, Phase I, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41719502-carfilzomib:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-26
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41719502-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-41719502-carfilzomib-v1
- Content SHA-256: `f0c34666e38af50841af889b983dfcf7b3c83dde35f167a86d920f5c3769316e`

### Claims and source pins

#### Headline

Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma. ([`pubmed-observation-pmid-41719502-2026-09-26-901673ab845d`](#source-pubmed-observation-pmid-41719502-2026-09-26-901673ab845d))

#### Summary

PubMed lists PMID 41719502 in Blood advances as Journal Article, Clinical Trial, Phase II, Clinical Trial, Phase I, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41719502-2026-09-26-901673ab845d`](#source-pubmed-observation-pmid-41719502-2026-09-26-901673ab845d))

#### Paragraph 1

PubMed lists PMID 41719502 in Blood advances as Journal Article, Clinical Trial, Phase II, Clinical Trial, Phase I, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41719502-2026-09-26-901673ab845d`](#source-pubmed-observation-pmid-41719502-2026-09-26-901673ab845d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41719502-2026-09-26-901673ab845d`](#source-pubmed-observation-pmid-41719502-2026-09-26-901673ab845d))

### Sources

<a id="source-pubmed-observation-pmid-41719502-2026-09-26-901673ab845d"></a>
- **Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma. · retained source version 1:2026-09-26:current:901673ab845dbde1dc67196cfca737df97d6f752e872955a5348eef9d0503bce** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41719502/) (`pubmed-observation-pmid-41719502-2026-09-26-901673ab845d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-41719502-carfilzomib-v1 SHA-256: f0c34666e38af50841af889b983dfcf7b3c83dde35f167a86d920f5c3769316e.

---

<a id="pubmed-pmid-41942646-carfilzomib-v1"></a>

## Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial.

> PubMed lists PMID 41942646 in Nature medicine as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, with publication-date metadata of 2026-04-06 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41942646-carfilzomib:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41942646-carfilzomib/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-41942646-carfilzomib-v1
- Content SHA-256: `c9281be97d88a00fd4192d6ee0840e11ba47ba24fe22d5ea61c764070ed3d17d`

### Claims and source pins

#### Headline

Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial. ([`pubmed-observation-pmid-41942646-2026-08-13-3bde6d4d2e88`](#source-pubmed-observation-pmid-41942646-2026-08-13-3bde6d4d2e88))

#### Summary

PubMed lists PMID 41942646 in Nature medicine as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, with publication-date metadata of 2026-04-06 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41942646-2026-08-13-3bde6d4d2e88`](#source-pubmed-observation-pmid-41942646-2026-08-13-3bde6d4d2e88))

#### Paragraph 1

PubMed lists PMID 41942646 in Nature medicine as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, with publication-date metadata of 2026-04-06 (day precision). PeptideScanner associated the retained record with the identity slug carfilzomib. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41942646-2026-08-13-3bde6d4d2e88`](#source-pubmed-observation-pmid-41942646-2026-08-13-3bde6d4d2e88))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41942646-2026-08-13-3bde6d4d2e88`](#source-pubmed-observation-pmid-41942646-2026-08-13-3bde6d4d2e88))

### Sources

<a id="source-pubmed-observation-pmid-41942646-2026-08-13-3bde6d4d2e88"></a>
- **Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial. · retained source version 1:2026-08-13:current:3bde6d4d2e883118dc7189481cb0cbd29673a6c6d29a0f9995936d04a54c33c4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41942646/) (`pubmed-observation-pmid-41942646-2026-08-13-3bde6d4d2e88`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/carfilzomib.json#pubmed-pmid-41942646-carfilzomib-v1 SHA-256: c9281be97d88a00fd4192d6ee0840e11ba47ba24fe22d5ea61c764070ed3d17d.

